Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds
Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds
Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren’s syndrome
https://pubmed.ncbi.nlm.nih.gov/33025899/
https://www.ncbi.nlm.nih.gov/pubmed/33025899?dopt=Abstract
TITLE:
Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren’s syndrome.
DESCRIPTION:
Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren’s syndrome.
Clin Exp Rheumatol. 2020 Sep 25;
Authors: Vehof J, Utheim TP, Bootsma H, Hammond CJ
Abstract
Primary Sjögren’s syndrome is a complex systemic autoimmune disorder that primarily affects exocrine glands such as the lacrimal glands. Dry eye disease is one of the most prevalent complications of Sjögren’s syndrome, affecting most patients. It significantly impairs quality of life and management is often difficult and unsatisfactory, in part due to weak correlation between symptoms and signs and poor recognition of the three main subtypes aqueous-deficient, evaporative and neuropathic dry eye. This review provides an overview of key aspects of dry eye disease, such as its multifactorial aetiology and recent insights into pathophysiology. The uses and pitfalls of commonly-used diagnostic tests for dry eye are reviewed, as well as the increasing number of new imaging technologies and biomarkers to refine diagnosis. There are many current and emerging treatment options for dry eye in Sjögren’s syndrome, but high-level evidence of efficacy is mostly lacking, as are evidence-based treatment algorithms. All these aspects make the management of dry eye in Sjögren’s syndrome challenging.
PMID: 33025899 [PubMed – as supplied by publisher]
PMID:
PubMed:33025899
DATE FOUND:
10/08/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/33025899?dopt=Abstract
Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests
Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests
Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests
Blockade of Th17 response by IL-38 in primary Sjögren’s syndrome
https://www.sciencedirect.com/science/article/pii/S016158902030482X?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/32950755?dopt=Abstract
TITLE:
Blockade of Th17 response by IL-38 in primary Sjögren’s syndrome.
DESCRIPTION:
Blockade of Th17 response by IL-38 in primary Sjögren’s syndrome.
Mol Immunol. 2020 Sep 17;127:107-111
Authors: Luo D, Chen Y, Zhou N, Li T, Wang H
Abstract
BACKGROUND: T helper 17 (Th17) cell responses were involved in the pathophysiology of primary Sjögren’s syndrome (pSS). IL-38 has been reported to inhibit the secretion of chemokines involved in Th17 pathway. This study aimed to explore the regulation of Th17 response by IL-38 in pSS.
METHODS: Twenty-four pSS patients, 15 non-pSS control, and 13 health subjects were recruited. The expression of IL-38 and Th17 cytokines were detected and compared between pSS and controls. Human peripheral blood mononuclear cells (PBMCs) and minor salivary gland mononuclear cells (MSGMs) were purified and stimulated by IL-38. The differentiation and function of Th17 cells were evaluated by PCR and enzyme-linked immunosorbent assay (ELISA).
RESULTS: The pSS patients presented with significantly lower expression of IL-38 and higher Th17 cytokines (IL-17 and IL-23) compared with both non-pSS and healthy controls. The IL-38 inhibited the differentiation and function of Th17 responses from PBMCs and MSGMs. The IL-38 treatment could inhibit the Th17 response in mice model.
CONCLUSIONS: IL-38 inhibits T helper 17 type responses in pSS, suggesting that IL-38 may be used as potential treatment target in pSS.
PMID: 32950755 [PubMed – as supplied by publisher]
PMID:
PubMed:32950755
DATE FOUND:
09/21/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32950755?dopt=Abstract
Gpr125 Plays Critical Roles in Lacrimal Myoepithelia and Tear Film [Preprint]
https://www.biorxiv.org/content/10.1101/2020.09.15.296749v1.full
Gpr125 Plays Critical Roles in Lacrimal Myoepithelia and Tear Film
Elena Spina, Rebecca Handlin, Julia Simundza, Angela Incassati, Muneeb Faiq, Anoop Sainulabdeen, Kevin C Chan, Pamela Cowin
doi: https://doi.org/10.1101/2020.09.15.296749
Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
https://clinicaltrials.gov/ct2/show/NCT04546542?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F31%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
DESCRIPTION:
Condition: Sjogren’s Syndrome
Intervention: Other: Parallel Assignment
Sponsor: University of Sao Paulo General Hospital
Not yet recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT04546542
FIRST POSTED:
Mon, 14 Sep 2020 12:00:00 EDT
LAST UPDATE POSTED:
09/14/20 07:10AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04546542?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F31%2F2020&lupd_d=14&sort=nwst
CP-25, a compound derived from paeoniflorin: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases
https://www.nature.com/articles/s41401-020-00510-6
https://www.ncbi.nlm.nih.gov/pubmed/32884075?dopt=Abstract
TITLE:
CP-25, a compound derived from paeoniflorin: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases.
DESCRIPTION:
Related Articles
CP-25, a compound derived from paeoniflorin: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases.
Acta Pharmacol Sin. 2020 Sep 03;:
Authors: Yang XZ, Wei W
Abstract
Total glycoside of paeony (TGP) has been widely used to treat inflammation and immune diseases in China. Paeoniflorin (Pae) is the major active component of TGP. Although TGP has few adverse drug reactions, the slow onset and low bioavailability of Pae limit its clinical use. Enhanced efficacy without increased toxicity is pursued in developing new agents for inflammation and immune diseases. As a result, paeoniflorin-6′-O-benzene sulfonate (CP-25) derived from Pae, is developed in our group, and exhibits superior bioavailability and efficacy than Pae. Here we describe the development process and research advance on CP-25. The pharmacokinetic parameters of CP-25 and Pae were compared in vivo and in vitro. CP-25 was also compared with the first-line drugs methotrexate, leflunomide, and hydroxychloroquine in their efficacy and adverse effects in arthritis animal models and experimental Sjögren’s syndrome. We summarize the regulatory effects of CP-25 on inflammation and immune-related cells, elucidate the possible mechanisms, and analyze the therapeutic prospects of CP-25 in inflammation and immune diseases, as well as the diseases related to its potential target G-protein-coupled receptor kinases 2 (GRK2). This review suggests that CP-25 is a promising agent in the treatment of inflammation and immune diseases, which requires extensive investigation in the future. Meanwhile, this review provides new ideas about the development of anti-inflammatory immune drugs.
PMID: 32884075 [PubMed – as supplied by publisher]
PMID:
PubMed:32884075
DATE FOUND:
09/05/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32884075?dopt=Abstract
Understanding the Complexity of Sjögren’s Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms
https://www.mdpi.com/2077-0383/9/9/2821/htm
https://www.ncbi.nlm.nih.gov/pubmed/32878252?dopt=Abstract
TITLE:
Understanding the Complexity of Sjögren’s Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms.
DESCRIPTION:
Related Articles
Understanding the Complexity of Sjögren’s Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms.
J Clin Med. 2020 Aug 31;9(9):
Authors: Sisto M, Ribatti D, Lisi S
Abstract
Sjögren’s syndrome (SS) is a systemic autoimmune inflammatory disease with a poorly defined aetiology, which targets exocrine glands (particularly salivary and lachrymal glands), affecting the secretory function. Patients suffering from SS exhibit persistent xerostomia and keratoconjunctivitis sicca. It is now widely acknowledged that a chronic grade of inflammation plays a central role in the initiation, progression, and development of SS. Consistent with its key role in organizing inflammatory responses, numerous recent studies have shown involvement of the transcription factor nuclear factor κ (kappa)-light-chain-enhancer of activated B cells (NF-κB) in the development of this disease. Therefore, chronic inflammation is considered as a critical factor in the disease aetiology, offering hope for the development of new drugs for treatment. The purpose of this review is to describe the current knowledge about the NF-κB-mediated molecular events implicated in the pathogenesis of SS.
PMID: 32878252 [PubMed]
PMID:
PubMed:32878252
DATE FOUND:
09/04/20 06:00AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32878252?dopt=Abstract
Adjuvant rituximab improves sensory ataxia in CIDP-related Sjögren syndrome
https://casereports.bmj.com/content/13/8/e234681
https://www.ncbi.nlm.nih.gov/pubmed/32847874?dopt=Abstract
TITLE:
Adjuvant rituximab improves sensory ataxia in CIDP-related Sjögren syndrome.
DESCRIPTION:
Related Articles
Adjuvant rituximab improves sensory ataxia in CIDP-related Sjögren syndrome.
BMJ Case Rep. 2020 Aug 26;13(8):
Authors: Rocha R, Correia F, Santos A, Martins J
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune neuropathy characterised by insidious onset, progressive course, proximal and distal symmetrical weakness, and sensory impairment. It may affect patients of any age with varying degrees of clinical involvement and response rates to existing treatments. Sjögren syndrome (SS) is a systemic autoimmune disorder that primarily affects the exocrine glands causing a sicca syndrome. It may affect the peripheral nervous system, usually causing painful small fibre or pure sensory axonal neuropathy, ganglioneuronopathy or a predominantly sensory CIDP. We report the case of a 71-year-old man diagnosed with a debilitating and difficult-to-treat CIDP who, 5 years later, developed SS with pulmonary involvement. Due to lack of response to treatments other than periodic intravenous immunoglobulin (IVIg) every 12 days, we started adjuvant treatment with rituximab which increased the time interval between IVIg therapies by 50%, providing better quality of life for the patient.
PMID: 32847874 [PubMed – in process]
PMID:
PubMed:32847874
DATE FOUND:
08/28/20 06:02AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32847874?dopt=Abstract
TrueTear in Sjogren’s Disease Patients
https://clinicaltrials.gov/ct2/show/NCT03719885?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F11%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
TrueTear in Sjogren’s Disease Patients
DESCRIPTION:
Conditions: Dry Eye Syndromes; Sjogren’s Syndrome
Intervention: Device: TrueTear Intranasal Tear Neurostimulator
Sponsors: University of Pennsylvania; Allergan
Completed
CLINICALTRIALS.GOV IDENTIFIER:
NCT03719885
FIRST POSTED:
Thu, 25 Oct 2018 12:00:00 EDT
LAST UPDATE POSTED:
08/25/20 07:09AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03719885?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F11%2F2020&lupd_d=14&sort=nwst
MicroRNAs and Autoimmune-Mediated Eye Diseases
https://www.frontiersin.org/articles/10.3389/fcell.2020.00818/full
https://www.ncbi.nlm.nih.gov/pubmed/32974350?dopt=Abstract
TITLE:
MicroRNAs and Autoimmune-Mediated Eye Diseases.
DESCRIPTION:
Related Articles
MicroRNAs and Autoimmune-Mediated Eye Diseases.
Front Cell Dev Biol. 2020;8:818
Authors: Wei Y, Li N, Zhao L, Yang C, Ma B, Li X, Wei R, Nian H
Abstract
MicroRNAs (miRNAs) are evolutionarily conserved short non-coding RNAs that act at post-transcriptional regulation of gene expression by destroying target messenger RNA or inhibiting its translation. Recently, miRNAs have been identified as important regulators in autoimmunity. Aberrant expression and function of miRNAs can lead to dysfunction of immune system and mediate autoimmune disorders. Here, we summarize the roles of miRNAs that have been implicated in three representative ocular autoimmune disorders, including autoimmune uveitis, Grave’s ophthalmopathy, and Sjögren’s syndrome dry eye, and discuss the potential of miRNAs as biomarkers and therapeutic targets for the diagnosis and treatment of these diseases.
PMID: 32974350 [PubMed]
PMID:
PubMed:32974350
DATE FOUND:
09/26/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32974350?dopt=Abstract
The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies
https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ20-0178/_article
https://www.ncbi.nlm.nih.gov/pubmed/32814731?dopt=Abstract
TITLE:
The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies.
DESCRIPTION:
Related Articles
The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies.
Endocr J. 2020 Aug 18;:
Authors: Wang L, Deng Y
Abstract
Androgen regulates the function of lacrimal and meibomian glands, and its deficiency is a pathological factor underlying dry eye disease (DED). However, no androgen has been approved for treating DED due to lack of definite evidence regarding its efficacy and safety in clinics. In this systematic review, we have summarized the clinical studies on the safety and efficacy of androgen replacement therapy (ART) for DED. Medline (via Pubmed), Embase, Clinicaltrials.gov, Wanfang and Chinese Clinical Trials Registry Database were searched for the relevant prospective studies, and 7 studies wherein androgen was applied topically via eye drops or systemically via oral or transdermal administration were included. The quality of these studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias and methodological index for non-randomized studies. Most studies showed that androgen effectively improved dry eye-related symptoms and increased tear secretion. Furthermore, elderly men and peri-menopausal women with lower levels of circulating androgens responded better to ART. However, one study involving patients with Sjögren’s syndrome showed no improvement in the ART group compared to the placebo control, or to the baseline level. Adverse effects were also common but limited to mild skin problems. In conclusion, androgen is a potential treatment for dry eye disease, especially for people with primary androgen deficiency. Short-term application is relatively safe.
PMID: 32814731 [PubMed – as supplied by publisher]
PMID:
PubMed:32814731
DATE FOUND:
08/21/20 02:21PM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32814731?dopt=Abstract
Nuclease Therapy Improves Severe Fatigue in Primary Sjögren’s Syndrome: A Randomized Clinical Trial
https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41489
https://www.ncbi.nlm.nih.gov/pubmed/32798283?dopt=Abstract
TITLE:
Nuclease Therapy Improves Severe Fatigue in Primary Sjögren’s Syndrome: A Randomized Clinical Trial.
DESCRIPTION:
Nuclease Therapy Improves Severe Fatigue in Primary Sjögren’s Syndrome: A Randomized Clinical Trial.
Arthritis Rheumatol. 2020 Aug 15;:
Authors: Posada J, Valadkhan S, Burge D, Davies K, Tarn J, Casement J, Jobling K, Gallagher P, Wilson D, Barone F, Fisher BA, Ng WF
Abstract
OBJECTIVE: To assess the safety and efficacy of RSLV-132, an RNase Fc fusion protein in a phase II randomized, double-blind, placebo-controlled clinical trial in patients with primary Sjögren’s syndrome (pSS).
METHODS: Thirty patients were randomized to receive intravenous RSLV-132 or placebo, weekly for two weeks then every two weeks for twelve weeks. Eight subjects received placebo and twenty received RSLV-132, 10 mg/kg. Clinical efficacy measures included the European League Against Rheumatism (EULAR) Sjögren’s syndrome disease activity index (ESSDAI), EULAR Sjögren’s syndrome patient reported index (ESSPRI), FACIT fatigue (FACIT-F), and profile of fatigue (ProF), and the digit symbol substitution test (DSST).
RESULTS: Patients randomized to RSLV-132, but not placebo, experienced clinically meaningful improvements in ESSPRI, FACIT-F, ProF, and DSST. This improvement was correlated with increased expression of selected interferon-inducible genes.
CONCLUSION: Administration of RSLV-132 improved severe fatigue in pSS patients as determined by four independent measures of fatigue.
PMID: 32798283 [PubMed – as supplied by publisher]
PMID:
PubMed:32798283
DATE FOUND:
08/17/20 06:03AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32798283?dopt=Abstract
Ask the Expert: CBD Oil and Sjögren’s
https://www.sjogrens.org/blog/2020/ask-the-expert-cbd-oil-and-sjogrens
Ask the Expert: CBD Oil and Sjögren’s
Ask the Expert, Symptoms, Treatment — Aug 12, 2020
OMRF needs participants for Sjögren’s Syndrome study
OMRF needs participants for Sjögren’s Syndrome study
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome
https://clinicaltrials.gov/ct2/show/NCT03905525?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F14%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome
DESCRIPTION:
Condition: Sjögren Syndrome
Interventions: Drug: CFZ533; Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT03905525
FIRST POSTED:
Fri, 05 Apr 2019 12:00:00 EDT
LAST UPDATE POSTED:
10/28/19 11:40AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03905525?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F14%2F2019&lupd_d=14&sort=nwst
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome
https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr
https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome Phase Ib-IIa Placebo-Controlled Clinical Trial and Associated Mechanistic Studies
DESCRIPTION:
Condition: Sjogren’s Syndrome
Interventions: Drug: tofacitinib; Other: Placebo
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Not yet recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT04496960
FIRST POSTED:
Tue, 04 Aug 2020 12:00:00 EDT
LAST UPDATE POSTED:
08/04/20 07:19AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst
Involvement of Immune Cells Derived From the Intestine in Sjogren’s Syndrome
https://clinicaltrials.gov/ct2/show/NCT03841318?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F09%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
Involvement of Immune Cells Derived From the Intestine in Sjogren’s Syndrome
DESCRIPTION:
Condition: Sjogren’s Syndrome
Interventions: Biological: blood sample; Biological: biopsy of the labial salivary gland
Sponsor: University Hospital, Bordeaux
Not yet recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT03841318
FIRST POSTED:
Fri, 15 Feb 2019 12:00:00 EST
LAST UPDATE POSTED:
03/23/20 12:38PM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03841318?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F09%2F2020&lupd_d=14&sort=nwst
Advances in treatments for Sjögren’s syndrome: the glass is half full
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30220-4/fulltext
Advances in treatments for Sjögren’s syndrome: the glass is half full
Renaud Felten
Jacques Eric Gottenberg
Published:August 03, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30220-4
Chinese herbal medicine SS-1 inhibits T cell activation and abrogates TH responses in Sjögren’s syndrome
https://www.sciencedirect.com/science/article/pii/S0929664620303363?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/32741737?dopt=Abstract
TITLE:
Chinese herbal medicine SS-1 inhibits T cell activation and abrogates TH responses in Sjögren’s syndrome.
DESCRIPTION:
Related Articles
Chinese herbal medicine SS-1 inhibits T cell activation and abrogates TH responses in Sjögren’s syndrome.
J Formos Med Assoc. 2020 Jul 30;:
Authors: Lee GA, Chang CM, Wu YC, Ma RY, Chen CY, Hsue YT, Liao NS, Chang HH
Abstract
BACKGROUND/PURPOSE: Sjögren’s syndrome (SS) is an autoimmune disease and its conventional treatment has exhibited limited therapeutic efficacy. Traditional Chinese medicine has been demonstrated to ameliorate the sicca symptoms of SS by decreasing the level of TH1 and TH2 cytokines and increasing salivary flow rate. A newly designed traditional Chinese medicine, SS-1, showed improved efficacy in alleviating the dryness symptoms of SS patients in the National Taiwan SS cohort investigation. Here, we investigated the effect of SS-1 on T cell responses.
METHODS: SS-1 was authenticated and its major compounds were verified by high-performance liquid chromatography. We examined the effects of SS-1 on the activation and TH1, TH2, and TH17 polarization of murine T cells. We also determined the level of TH1, TH2, and TH17 cytokine RNA in peripheral blood mononuclear cells of SS patients before and after SS-1 treatment.
RESULTS: SS-1 treatment inhibits the activation and TH1, TH2, and IL-17A+IFNγ+ TH polarization of murine T cells. SS-1 treatment also significantly reduces IFN-γ, IL-4, and IL-13 expression, and moderately reduces IL-17A expression in peripheral blood mononuclear cells of SS patients.
CONCLUSION: Our results suggest that SS-1 inhibits T cell activation and diminishes TH1, TH2, and IL-17+IFN-γ+ TH responses in SS patients.
PMID: 32741737 [PubMed – as supplied by publisher]
PMID:
PubMed:32741737
DATE FOUND:
08/04/20 06:03AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32741737?dopt=Abstract
Intravenous Immunoglobulins for the Treatment of Primary Sjögren’s Syndrome Associated Painful Sensory Neuropathies
https://clinicaltrials.gov/ct2/show/NCT03700138?type=Intr
https://clinicaltrials.gov/ct2/show/NCT03700138?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F13%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
Intravenous Immunoglobulins for the Treatment of Primary Sjögren’s Syndrome Associated Painful Sensory Neuropathies
DESCRIPTION:
Condition: Primary Sjögren’s Syndrome Painful Sensory Neuropathies
Interventions: Drug: Privigen® 100mg/ml at the dose of 2g/kg of body weight; Drug: NaCl 0,9%
Sponsor: University Hospital, Strasbourg, France
Recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT03700138
FIRST POSTED:
Tue, 09 Oct 2018 12:00:00 EDT
LAST UPDATE POSTED:
07/27/20 07:18AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03700138?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F13%2F2020&lupd_d=14&sort=nwst
Mesenchymal Stem Cell Therapy for Oral Inflammatory Diseases: Research Progress and Future Perspectives
https://www.eurekaselect.com/184122/article
https://www.ncbi.nlm.nih.gov/pubmed/32713335?dopt=Abstract
TITLE:
Mesenchymal Stem Cell Therapy for Oral Inflammatory Diseases: Research Progress and Future Perspectives.
DESCRIPTION:
Related Articles
Mesenchymal Stem Cell Therapy for Oral Inflammatory Diseases: Research Progress and Future Perspectives.
Curr Stem Cell Res Ther. 2020 Jul 26;:
Authors: Gong W, Wang F, He Y, Heath B, Zeng X, Zhang D, Chen Q
Abstract
Mesenchymal stem cell (MSC) therapy for clinical diseases associated with inflammation and tissue damage has become a progressive treatment strategy. MSCs have unique biological functions, such as homing, immune regulation, and differentiation capabilities, which provide the prerequisites for treatment of clinical diseases. Oral diseases are often associated with abnormal immune regulation and epithelial tissue damage. In this review, we summarize previous studies that use MSC therapy to treat various oral inflammatory diseases, including oral ulceration, allergic diseases, chemo/radiotherapy-induced oral mucositis, periodontitis, osteonecrosis of the jaw, Sjögren’s syndrome (SS), among other similar diseases. We highlight MSC treatment as a promising approach in the management of oral inflammatory diseases, and discuss the obstacles that remain and must be overcome for MSC treatment to thrive in the future.
PMID: 32713335 [PubMed – as supplied by publisher]
PMID:
PubMed:32713335
DATE FOUND:
07/28/20 06:15AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32713335?dopt=Abstract
Injection of CD40 DNA vaccine ameliorates the autoimmune pathology of Non-obese Diabetic Mice with Sjögren’s Syndrome
https://www.sciencedirect.com/science/article/abs/pii/S0165247820303539?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/32707129?dopt=Abstract
TITLE:
Injection of CD40 DNA vaccine ameliorates the autoimmune pathology of Non-obese Diabetic Mice with Sjögren’s Syndrome.
DESCRIPTION:
Related Articles
Injection of CD40 DNA vaccine ameliorates the autoimmune pathology of Non-obese Diabetic Mice with Sjögren’s Syndrome.
Immunol Lett. 2020 Jul 21;:
Authors: Zhou YB, Yuan X, Wang QK, Zhang H, Wang GS, Li XP, Wang Y, Harris D, Li XM
Abstract
BACKGROUND: Overexpression of CD40 has been reported in patients with primary Sjögren’s syndrome (pSS). The increased CD40 expression promote autoimmune response and enhance inflammation in pSS. The aim of this study is to block CD40-CD154 interaction with CD40 DNA vaccine to slow the disease progression of SS in non-obese diabetic (NOD) mice.
METHODS: Female NOD mice were treated with CD40 DNA vaccine, empty vector and normal saline. The salivary flow rate was measured, whereas lymphocytes infiltration in the salivary glands was assessed by histopathology. Expression of CD40 and B220 in salivary were examined by immunohistochemistry. Splenic lymphocyte phenotypes were analyzed by flow cytometry. CD40, IL-1β, TNF-α and IL-6 levels in the salivary glands were detected by PCR. Serum anti-CD40 antibody was measured by ELISA. Serum anti-nuclear antibody (ANA) was monitored by immunofluorescence.
RESULTS: NOD mice treated with CD40 DNA vaccine showed higher levels of anti-CD40 antibody compared with the controls. The expression of CD40 in the salivary glands of NOD mice in CD40 DNA vaccine group was decreased. The infiltration of lymphocytes was reduced in the salivary glands and saliva secretion was increased in the treatment group. The expression level of TNF-α and IL-6 in salivary glands were declined. The splenic dendritic cell and plasma cell populations were reduced and the level of ANA was decreased in NOD mice with CD40 DNA vaccine treatment.
CONCLUSIONS: CD40 DNA vaccine inhibits the immune response and reduce inflammation in epithelial tissues SS in non-obese diabetic (NOD) mice, suggesting that CD40 DNA vaccine could be a new therapeutic approach in treatment of pSS.
PMID: 32707129 [PubMed – as supplied by publisher]
PMID:
PubMed:32707129
DATE FOUND:
07/27/20 01:13PM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32707129?dopt=Abstract
University of Queensland and CSL Limited partner up to progress treatments for Sjogren’s syndrome
https://www.uq.edu.au/news/article/2020/07/partnership-progress-treatments-sjogren%E2%80%99s-syndrome
Partnership to progress treatments for Sjogren’s syndrome
The University of Queensland and global biotechnology company CSL Limited
Current State of Knowledge on Primary Sjögren’s Syndrome, an Autoimmune Exocrinopathy
https://www.mdpi.com/2077-0383/9/7/2299
https://www.ncbi.nlm.nih.gov/pubmed/32698400?dopt=Abstract
TITLE:
Current State of Knowledge on Primary Sjögren’s Syndrome, an Autoimmune Exocrinopathy.
DESCRIPTION:
Related Articles
Current State of Knowledge on Primary Sjögren’s Syndrome, an Autoimmune Exocrinopathy.
J Clin Med. 2020 Jul 20;9(7):
Authors: Parisis D, Chivasso C, Perret J, Soyfoo MS, Delporte C
Abstract
Primary Sjögren’s syndrome (pSS) is a chronic systemic autoimmune rheumatic disease characterized by lymphoplasmacytic infiltration of the salivary and lacrimal glands, whereby sicca syndrome and/or systemic manifestations are the clinical hallmarks, associated with a particular autoantibody profile. pSS is the most frequent connective tissue disease after rheumatoid arthritis, affecting 0.3-3% of the population. Women are more prone to develop pSS than men, with a sex ratio of 9:1. Considered in the past as innocent collateral passive victims of autoimmunity, the epithelial cells of the salivary glands are now known to play an active role in the pathogenesis of the disease. The aetiology of the “autoimmune epithelitis” still remains unknown, but certainly involves genetic, environmental and hormonal factors. Later during the disease evolution, the subsequent chronic activation of B cells can lead to the development of systemic manifestations or non-Hodgkin’s lymphoma. The aim of the present comprehensive review is to provide the current state of knowledge on pSS. The review addresses the clinical manifestations and complications of the disease, the diagnostic workup, the pathogenic mechanisms and the therapeutic approaches.
PMID: 32698400 [PubMed]
PMID:
PubMed:32698400
DATE FOUND:
07/24/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32698400?dopt=Abstract
Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sjögren’s syndrome: a real-world study [PDF]
http://apm.amegroups.com/article/view/47479/pdf
https://www.ncbi.nlm.nih.gov/pubmed/32692242?dopt=Abstract
TITLE:
Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sjögren’s syndrome: a real-world study.
DESCRIPTION:
Related Articles
Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sjögren’s syndrome: a real-world study.
Ann Palliat Med. 2020 Jul 20;:
Authors: Guan P, Sun C, Chen Z, Chen J, Ran R
Abstract
BACKGROUND: Patients with primary Sjögren’s syndrome (pSS) often suffer from sleep disturbance. Studies suggest it may be related to symptoms, including xerostomia and dry eyes. Clinical studies have confirmed that hydroxychloroquine (HCQ) has a definite effect on pSS, but there is no clear report about its effect on sleep disorders in pSS patients.
METHODS: A total of 383 pSS patients were enrolled and followed up. The Pittsburgh Sleep Quality Index (PSQI) was used to evaluate the sleep quality of the patients, and the World Health Organization Quality of Life Brief Version (WHOQOL-BREF) scale was used to evaluate the quality of life (QoL) of patients. The European League assessed the patient’s condition against Rheumatism Sjögren’s syndrome patients reported index (ESSPRI). According to PSQI, patients were divided into two groups: good sleep group (GSG) and poor sleep group (PSG). The risk factors of sleep disorder are analyzed by univariate and multivariate analysis. The patients were further divided into HCQ-administered group and non-administered group, and the differences of baseline characteristics and outcome in follow-up between the two groups were compared.
RESULTS: There were 208 patients with PSG (54.3%) and 175 patients with GSG (45.7%). Further, there is no statistical difference between the two groups in baseline data. Also, there were 112 cases (53.8%) and 118 cases (67.4%) taking HCQ in the two groups, respectively, P=0.007. Univariate and multivariate analysis showed that long-term use of HCQ, menopause, and income were related to sleep quality. The patients were divided into the HCQ-administered group (n=230) and non-administered group (n=153) according to whether they took HCQ. One hundred eighteen patients (51.3%) in the HCQ-administered group had a good sleep, and 58 patients in the non- administered group had a good sleep (37.9%), P<0.05. At followup, the PSQI of the two groups were 7.3±2.1 vs. 8.1±2.4, respectively, P<0.05 and the ESSPRI were 4.9±1.1 vs. 5.4±1.3, P<0.05. The QoL of the two groups of patients was statistically different in all four dimensions, P<0.05. CONCLUSIONS: Long-term use of HCQ can reduce the risk of sleep disturbance in patients with primary Sjögren's syndrome. PMID: 32692242 [PubMed - as supplied by publisher] PMID: PubMed:32692242 DATE FOUND: 07/22/20 06:01AM LINK / URL: https://www.ncbi.nlm.nih.gov/pubmed/32692242?dopt=Abstract
Lung Involvement in Primary Sjögren’s Syndrome-An Under-Diagnosed Entity
https://www.frontiersin.org/articles/10.3389/fmed.2020.00332/full
https://www.ncbi.nlm.nih.gov/pubmed/32766261?dopt=Abstract
TITLE:
Lung Involvement in Primary Sjögren’s Syndrome-An Under-Diagnosed Entity.
DESCRIPTION:
Related Articles
Lung Involvement in Primary Sjögren’s Syndrome-An Under-Diagnosed Entity.
Front Med (Lausanne). 2020;7:332
Authors: Sogkas G, Hirsch S, Olsson KM, Hinrichs JB, Thiele T, Seeliger T, Skripuletz T, Schmidt RE, Witte T, Jablonka A, Ernst D
Abstract
Interstitial lung disease (ILD) represents a frequent extra-glandular manifestation of primary Sjögren’s Syndrome (pSS). Limited published data regarding phenotyping and treatment exists. Advances in managing specific ILD phenotypes have not been comprehensively explored in patients with coexisting pSS. This retrospective study aimed to phenotype lung diseases occurring in a well-described pSS-ILD cohort and describe treatment course and outcomes. Between April 2018 and February 2020, all pSS patients attending our Outpatient clinic were screened for possible lung involvement. Clinical, laboratory and high-resolution computed tomography (HRCT) findings were analyzed. Patients were classified according to HRCT findings into five groups: usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP), combined pulmonary fibrosis and emphysema (CPFE), and non-specific-ILD. Lung involvement was confirmed in 31/268 pSS patients (13%). One-third (10/31) of pSS-ILD patients were Ro/SSA antibody negative. ILD at pSS diagnosis was present in 19/31 (61%) patients. The commonest phenotype was UIP n = 13 (43%), followed by NSIP n = 9 (29%), DIP n = 2 (6 %), CPFE n = 2 (6 %), and non-specific-ILD n = 5 (16%). Forced vital capacity (FVC) and carbon monoxide diffusion capacity (DLCO) appeared lower in UIP and DIP, without reaching a significant difference. Treatment focused universally on intensified immunosuppression, with 13/31 patients (42%) receiving cyclophosphamide. No anti-fibrotic treatments were used. Median follow-up was 38.2 [12.4-119.6] months. Lung involvement in pSS is heterogeneous. Better phenotyping and tailored treatment may improve outcomes and requires further evaluation in larger prospective studies.
PMID: 32766261 [PubMed – as supplied by publisher]
PMID:
PubMed:32766261
DATE FOUND:
08/09/20 06:03AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32766261?dopt=Abstract
Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy for Sjogren’s
Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy
Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy
Two Projects Using Hydrogel Biomaterials to Stimulate Tissue Regeneration Move Forward with New Funding
https://www.ucsf.edu/news/2020/07/418091/two-projects-using-hydrogel-biomaterials-stimulate-tissue-regeneration-move
Two Projects Using Hydrogel Biomaterials to Stimulate Tissue Regeneration Move Forward with New Funding
Novel Cytokine Multiplex Assay for Tear Fluid Analysis in Sjogren’s Syndrome
https://www.tandfonline.com/doi/abs/10.1080/09273948.2020.1767792?journalCode=ioii20
https://www.ncbi.nlm.nih.gov/pubmed/32657632?dopt=Abstract
TITLE:
Novel Cytokine Multiplex Assay for Tear Fluid Analysis in Sjogren’s Syndrome.
DESCRIPTION:
Novel Cytokine Multiplex Assay for Tear Fluid Analysis in Sjogren’s Syndrome.
Ocul Immunol Inflamm. 2020 Jul 13;:1-6
Authors: Willems B, Tong L, Minh TDT, Pham ND, Nguyen XH, Zumbansen M
Abstract
PURPOSE: Sjögren’s syndrome (SS) is an autoimmune disease associated with ocular surface inflammation. The goals of this study were to establish a novel bead-based protein microarray for simultaneous analysis of 11 cytokines from tear fluid collected with Schirmer strips from patients with SS.
METHODS: Three to ten microliter of tear fluid was collected with Schirmer strips from both eyes of 13 healthy controls and 12 SS patients. Tear fluid was eluted from the Schirmer strips, total protein and concentrations of 11 different cytokines were analyzed.
RESULTS: The multiplex assay demonstrated high assay sensitivity with LoDs between 1.4 and 55.3 pg/µl with mean CVs between 3.7% and 9.7%. Statistically significant upregulation (p < .005) of eight cytokines was observed in SS patients compared to controls. Additionally, four patient cytokine values showed a significant inverse correlation (r<-0.7) with Schirmer strip readings. CONCLUSION: The assay offers analytical reliability for quantification of biomarkers in small amounts of tear fluid with potential utility for treatment monitoring of SS and other types of Dry Eye Disease. PMID: 32657632 [PubMed - as supplied by publisher] PMID: PubMed:32657632 DATE FOUND: 07/14/20 06:04AM LINK / URL: https://www.ncbi.nlm.nih.gov/pubmed/32657632?dopt=Abstract
Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome
https://www.einnews.com/pr_news/521168729/luminary-therapeutics-and-case-western-reserve-university-enter-formal-collaboration-for-development-of-baff-car
Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome
Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome
MINNEAPOLIS, MN, USA, July 7, 2020 /EINPresswire.com/ — Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for use in CAR-T (chimeric antigen receptor T cells) constructs.
The BAFF target was discovered by Reshmi Parameswaran, PhD, an assistant professor at the Case Western Reserve School of Medicine and a faculty member in the Division of Hematology and Oncology, Department of Medicine, and the Seidman Cancer Center at University Hospitals (UH) in Cleveland.
Luminary intends to conduct IND-enabling non-clinical studies to support two clinical trials with its novel and proprietary non-viral autologous BAFF CAR-T (LMY-920) to treat Mantle Cell Lymphoma and Sjogren’s Syndrome. This BAFF target is unique in that it binds to three distinct receptors (BAFF, BCMA, and TACI). Additionally, this BAFF target avoids early B-Cells while targeting more mature B-Cells that express one of three antigens.
The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases such as Sjogren’s Syndrome
https://www.eurekaselect.com/183529/article
https://www.ncbi.nlm.nih.gov/pubmed/32634079?dopt=Abstract
TITLE:
The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
DESCRIPTION:
The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
Curr Pharm Des. 2020 Jul 07;:
Authors: Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR
Abstract
Chloroquine (CQ) and hydroxychloroquine (HCQ) are derivatives of the heterocyclic aromatic compound quinoline. These economical compounds were used as antimalarial agents for many years. Currently, they are used as monotherapy or in conjunction with other therapies for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome (SS) and antiphospholipid antibody syndrome (APS). Based on its effects on the modulation of the autophagy process, various clinical studies suggest that CQ and HCQ could be used in combination with other chemotherapeutics for the treatment of various types of cancer. Furthermore, the antiviral effects showed against Zika, Chikungunya, and HIV are due to the annulation of endosomal/lysosomal acidification. Recently, CQ and HCQ were approved for The U.S. Food and Drug Administration (FDA) for the treatment of infected patients with the coronavirus SARS-CoV-2, causing the disease originated in December 2019, namely COVID-2019. Several mechanisms have been proposed to explain the pharmacological effects of these drugs: 1) disruption of lysosomal and endosomal pH, 2) inhibition of protein secretion/expression, 3) inhibition of antigen presentation, 4) decrease of proinflammatory cytokines, 5) inhibition of autophagy, 6) induction of apoptosis and 7) inhibition of ion channels activation. Thus, evidence has shown that these structures are leader molecules that can be modified or combined with other therapeutic agents. In this review, we will discuss the most recent findings in the mechanisms of action of CQ and HCQ in the immune system, and the use of these antimalarial drugs on diseases.
PMID: 32634079 [PubMed – as supplied by publisher]
PMID:
PubMed:32634079
DATE FOUND:
07/08/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32634079?dopt=Abstract
Study identifies CP-25 as a potential drug for the treatment of primary Sjögren’s syndrome
New research published in Nature’s Laboratory Investigation shows that CP-25 “increased saliva flow, alleviated the salivary gland indexes, and improved tissue integrity” in a mouse model of primary Sjogren’s syndrome.
Researchers “identified the underlying mechanisms of the therapeutic effect of CP-25 and provided an experimental foundation for CP-25 as a potential drug in the treatment of the human autoimmune disorder pSS [primary Sjögren’s syndrome].”
The study titled, CP-25 alleviates antigen-induced experimental Sjögren’s syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration, was published on July 3, 2020 and funded by the National Nature Science Foundation of China, the Provincial Natural Science Research Project of Anhui Province, and the Key Projects of Anhui Province University Outstanding Youth Talent Fund.
Newsletter
Subscribe to email updates about CP-25 and other promising new treatments for Sjogren’s syndrome. (Free. One email per week. No spam.)
References
https://www.nature.com/articles/s41374-020-0453-0
https://pubmed.ncbi.nlm.nih.gov/32620868/
https://doi.org/10.1038/S41374-020-0453-0
Contact
Comments, questions, feedback? Send an email to michael@urgentresearch.com and say hello.
CP-25 alleviates antigen-induced experimental Sjögren’s syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration
https://www.nature.com/articles/s41374-020-0453-0
https://www.ncbi.nlm.nih.gov/pubmed/32620868?dopt=Abstract
TITLE:
CP-25 alleviates antigen-induced experimental Sjögren’s syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration.
DESCRIPTION:
Related Articles
CP-25 alleviates antigen-induced experimental Sjögren’s syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration.
Lab Invest. 2020 Jul 03;:
Authors: Wu H, Chen X, Gu F, Zhang P, Xu S, Liu Q, Zhang Q, Wang X, Wang C, Körner H, Wei W
Abstract
The etiology of primary Sjögren’s syndrome (pSS) remains unknown, and there is no complete curative drug. In this study, we treated a mouse model of the submandibular gland (SG) protein-immunized experimental Sjögren’s syndrome (ESS) with paeoniflorin-6′-O-benzene sulfonate (termed CP-25) to evaluate the potential therapeutic effects of CP-25. Through in vivo experiments, we found that CP-25 increased saliva flow, alleviated the salivary gland indexes, and improved tissue integrity in the ESS model. The viability of splenocytes and B-lymphocyte migration from spleen were reduced in ESS mice. Furthermore, CP-25 decreased the expression of IgG antibodies, anti-SSA and anti-SSB antibodies and modulated the levels of cytokines in the serum of SS mice. The numbers of total B lymphocytes, plasma cells (PCs), and memory B cells diminished in the salivary gland. Increased expression of the JAK1-STAT1-CXCL13 axis and IFNα was found in human tissue isolated from pSS patients. In vitro, after stimulation with IFNα, the levels of CXCL13 mRNA and CXCL13 in human salivary gland epithelial cells (HSGEC) increased, while CP-25 counteracted the secretion of CXCL13 and downregulated the expression of CXCL13. IFN-α activated the JAK1-STAT1/2-CXCL13 signaling pathway in HSGEC, which was negatively regulated by additional CP-25. As a consequence, B-cell migration was downregulated in coculture with IFN-α-stimulated HSGEC. Taken together, this study demonstrated that the therapeutic effects of CP-25 were associated with the inhibition of the JAK1-STAT1/2-CXCL13 signaling pathway in HSGEC, which impedes the migration of B cells into the salivary gland. We identified the underlying mechanisms of the therapeutic effect of CP-25 and provided an experimental foundation for CP-25 as a potential drug in the treatment of the human autoimmune disorder pSS.
PMID: 32620868 [PubMed – as supplied by publisher]
PMID:
PubMed:32620868
DATE FOUND:
07/06/20 06:02AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32620868?dopt=Abstract
M3 muscarinic acetylcholine receptor reactive Th17 cells in primary Sjögren’s syndrome
https://insight.jci.org/articles/view/135982
https://www.ncbi.nlm.nih.gov/pubmed/32614803?dopt=Abstract
TITLE:
M3 muscarinic acetylcholine receptor reactive Th17 cells in primary Sjögren’s syndrome.
DESCRIPTION:
M3 muscarinic acetylcholine receptor reactive Th17 cells in primary Sjögren’s syndrome.
JCI Insight. 2020 Jul 02;:
Authors: Abe S, Tsuboi H, Kudo H, Asashima H, Ono Y, Honda F, Takahashi H, Yagishita M, Hagiwara S, Kondo Y, Matsumoto I, Sumida T
Abstract
M3 muscarinic acetylcholine receptor (M3R) is one of the autoantigens associated with Sjögren’s syndrome (SS) and is localized in exocrine glands where disease specific inflammation occurs. The inflammatory lesion is characterized by infiltration of CD4+ T cells, including clonally expanded Th17 cells. We undertook this study to identify circulating M3R specific Th17 cells, and to determine functional properties of those cells. Using ELISpot method, we identified M3R reactive Th17 cells in the peripheral blood of patients with primary SS (pSS). Among examined 10 pSS, 10 healthy subjects (HS), and 5 IgG4-related disease (IgG4-RD) patients, M3R reactive IL-17 secreting cells were significantly increased in five pSS patients specifically. The commonest T cell epitope, which was analyzed and confirmed by co-culture of isolated CD4+ T cells with antigen presenting cells plus M3R peptides in vitro, was peptide 83-95 of M3R. Peptide recognition was partly in HLA DR restricted manner, confirmed by blocking assay. M3R reactive Th17 cells positivity correlated with higher titers of anti-M3R antibodies, whose systemic disease activity score tended to be higher. Our studies highlight the role of tissue specific autoantigen derived circulating Th17 cells in pSS, for which further work might lead to antigen specific targeted therapy.
PMID: 32614803 [PubMed – as supplied by publisher]
PMID:
PubMed:32614803
DATE FOUND:
07/03/20 06:00AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32614803?dopt=Abstract
Iguratimod treatment reduces disease activity in early primary Sjögren’s syndrome
https://www.tandfonline.com/doi/abs/10.1080/14397595.2020.1789335?journalCode=imor20
https://www.ncbi.nlm.nih.gov/pubmed/32613869?dopt=Abstract
TITLE:
Iguratimod treatment reduces disease activity in early primary Sjögren’s syndrome: an open-label pilot study.
DESCRIPTION:
Iguratimod treatment reduces disease activity in early primary Sjögren’s syndrome: an open-label pilot study.
Mod Rheumatol. 2020 Jul 02;:1-13
Authors: Chen H, Qi X, Li Y, Wu Q, Shi Q, Wang L, Li J, Zhao L, Zhang L, Zhou X, Fei Y, Liu J, Su J, Wu D, Yang Y, Jiang H, Zeng X, Zhang F, Zhao Y
Abstract
Objectives To evaluate the efficacy and safety of iguratimod in patients with early primary Sjögren’s syndrome (pSS).Methods Twenty-seven disease-modifying antirheumatic drug-naive female patients met the revised American-European Consensus Group criteria for pSS were enrolled in this open-label pilot study. Patients were treated with iguratimod 25 mg twice a day for 24 weeks. Disease activity was assessed with European League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI) and EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) at 12 and 24 weeks. Salivary and lacrimal gland function, laboratory and subjective variables were also assessed. Generalized estimating equations were used to analyze parameters over time.Results ESSDAI (median, 5 vs. 2 vs. 2, p < 0.01), IgG (median, 26.6 vs. 22.4 vs. 21.4 g/L, p < 0.01) and rheumatoid factor (median, 119.9 vs. 94.1 vs. 83.8 lU/mL, p < 0.01) levels decreased significantly during iguratimod treatment. ESSPRI, salivary and lacrimal gland function, fatigue and health-related quality of life did not change during treatment. One patient experienced thrombocytopenia, and no other serious adverse effects were observed.Conclusions In this study, iguratimod treatment is safe and effective for improving disease activity and laboratory parameters in early pSS patients. PMID: 32613869 [PubMed - as supplied by publisher] PMID: PubMed:32613869 DATE FOUND: 07/03/20 06:00AM LINK / URL: https://www.ncbi.nlm.nih.gov/pubmed/32613869?dopt=Abstract
Sjogren’s Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports
https://www.cureus.com/articles/28039-sjogrens-syndrome-and-clinical-benefits-of-low-dose-naltrexone-therapy-additional-case-reports
https://www.ncbi.nlm.nih.gov/pubmed/32765993?dopt=Abstract
TITLE:
Sjogren’s Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports.
DESCRIPTION:
Related Articles
Sjogren’s Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports.
Cureus. 2020 Jul 01;12(7):e8948
Authors: Zashin S
Abstract
Sjogren’s syndrome (SS) is a chronic autoimmune disorder that causes the inflammation of the lacrimal and salivary glands, resulting in dryness of the eyes and mouth. In addition, fatigue and musculoskeletal pain, often described as aching, are very common. Treatment directed towards alleviating the fatigue and pain associated with SS is currently very limited. In March of 2019, the first peer reviewed case report showing clinical improvement using low-dose naltrexone (LDN) in a patient with suspected SS was published in Cureus. This report describes two additional patients with SS whose conditions responded favorably to a treatment with LDN therapy. The first case is a 24-year-old female with documented SS. Her diagnosis was based on a history of dry eyes, dry mouth, joint pain, fatigue, and headache. In addition, she had very high measures of inflammation and a positive anti SS-A antibody. She improved clinically with LDN therapy. The second case is a 66-year-old female with documented SS based on a history of dry eyes and dry mouth, joint pain, and elevated anti-SSA and anti-SSB antibodies whose joint symptoms responded to treatment with LDN.
PMID: 32765993 [PubMed – as supplied by publisher]
PMID:
PubMed:32765993
DATE FOUND:
08/09/20 06:03AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32765993?dopt=Abstract
The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients
https://link.springer.com/article/10.1007%2Fs10792-020-01490-6
https://www.ncbi.nlm.nih.gov/pubmed/32607949?dopt=Abstract
TITLE:
The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients.
DESCRIPTION:
Related Articles
The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients.
Int Ophthalmol. 2020 Jul 01;:
Authors: Jiang W, Zhang L, Zhao Y, He X, Hu C, Liu Y
Abstract
PURPOSE: Primary Sjögren’s syndrome (pSS) has been proven as a systemic autoimmune disorder (such as Sjogren’s syndrome dry eye). This research aimed to evaluate potential treating effects of Iguratimod on pSS.
METHODS: Fifty pSS patients were enrolled and randomly divided into Conventional group and Iguratimod group. Improvement in pSS was evaluated every 4 weeks. pSS disease activity was evaluated with European League Against Rheumatism (EULAR) Sjögren’s syndrome disease activity index (ESSDAI). Symptoms were evaluated by determining EULAR Sjögren’s syndrome patient-reported index (ESSPRI), platelet (PLT), IgG and Schirmer I test. Peripheral blood B cell molecules (CD135, IgD, CD38, CD20) and human B cell-activating factor-receptor (BAFF-R) were analyzed with flow cytometry.
RESULTS: After treating for 12-weeks, pSS patients in Iguratimod and Conventional group showed a significant decrease in disease activity (ESSPRI, ESSDAI, PLT, IgG and Schirmer I test) comparing with baselines. Patients’ ESSPRI (2.92 ± 0.19) and disease activity of ESSDAI (4.32 ± 0.29), PLT (95.64 ± 1.86), IgG (13.0 ± 0.45) and Schirmer I test (4.67 ± 0.31) in Iguratimod group were significantly lower compared to Conventional group (4.64 ± 0.15, 5.8 ± 2.08, 77.44 ± 1.41, 16.5 ± 0.44 and 2.25 ± 0.11) (p < 0.0001). Changes of ESSPRI, ESSDAI, PLT, IgG and Schirmer I test were remarkable observed between two groups (p < 0.001). Iguratimod and Conventional treatment demonstrated a significant reduction in total B cells in pSS patients compared with pre-treatment. The pSS patients from Iguratimod and Conventional group showed a significant decreased BAFF-R (61.82 ± 1.52, 74.07 ± 1.11) and CD38+IgD+ (48.08 ± 0.92, 62.66 ± 1.12) on B cells after treatment compared with baseline (92.26 ± 0.32, 91.53 ± 0.45, 84.39 ± 0.59, 85.04 ± 0.46) (p < 0.001). After treating 12 weeks, BAFF-R, CD38+IgD+ expression in Iguratimod group decreased significantly compared to Conventional group (p < 0.001). CONCLUSIONS: Iguratimod alleviated symptoms and mediated adaptive-immunity balance by suppressing BAFF-R positive B cell in pSS patients. PMID: 32607949 [PubMed - as supplied by publisher] PMID: PubMed:32607949 DATE FOUND: 07/02/20 06:01AM LINK / URL: https://www.ncbi.nlm.nih.gov/pubmed/32607949?dopt=Abstract
Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjögren’s syndrome
https://link.springer.com/article/10.1007%2Fs00415-020-10033-z
https://www.ncbi.nlm.nih.gov/pubmed/32613444?dopt=Abstract
TITLE:
Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjögren’s syndrome.
DESCRIPTION:
Related Articles
Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjögren’s syndrome.
J Neurol. 2020 Jul 01;:
Authors: Pindi Sala T, Villedieu M, Damian L, Crave JC, Pautot V, Stojanovich L, Tervaert JWC, Cherin P, Belizna C
Abstract
The most common peripheral nervous system manifestations in Sjogren’s syndrome are small fiber sensory neuropathies (SFPN) and axonal sensorimotor polyneuropathies. Currently, treatment in small fiber neuropathy is mainly symptomatic and based on anti-depressors and anti-epileptics. The benefit of treatment with polyvalent immunoglobulins for SFPN has been reported in small series of patients, although transient in several cases. The medium-to-long-term effects of polyvalent immunoglobulins (Ig) in SFPN in patients with Sjogren’s syndrome who are refractory to conventional treatments remain an unmet medical need. We present our experience related to the persistent improvement of Ig in a case series of SFPN in Sjogren’s syndrome and relevant data in the literature regarding the benefits of immunoglobulins, for this indication.
PMID: 32613444 [PubMed – as supplied by publisher]
PMID:
PubMed:32613444
DATE FOUND:
07/03/20 06:00AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32613444?dopt=Abstract
Insight into Salivary Gland Aquaporins: AQP5 represents a potential therapeutic target for the treatment of xerostomia (dry mouth)
https://www.mdpi.com/2073-4409/9/6/1547
https://www.ncbi.nlm.nih.gov/pubmed/32630469?dopt=Abstract
TITLE:
Insight into Salivary Gland Aquaporins.
DESCRIPTION:
Related Articles
Insight into Salivary Gland Aquaporins.
Cells. 2020 Jun 25;9(6):
Authors: D’Agostino C, Elkashty OA, Chivasso C, Perret J, Tran SD, Delporte C
Abstract
The main role of salivary glands (SG) is the production and secretion of saliva, in which aquaporins (AQPs) play a key role by ensuring water flow. The AQPs are transmembrane channel proteins permeable to water to allow water transport across cell membranes according to osmotic gradient. This review gives an insight into SG AQPs. Indeed, it gives a summary of the expression and localization of AQPs in adult human, rat and mouse SG, as well as of their physiological role in SG function. Furthermore, the review provides a comprehensive view of the involvement of AQPs in pathological conditions affecting SG, including Sjögren’s syndrome, diabetes, agedness, head and neck cancer radiotherapy and SG cancer. These conditions are characterized by salivary hypofunction resulting in xerostomia. A specific focus is given on current and future therapeutic strategies aiming at AQPs to treat xerostomia. A deeper understanding of the AQPs involvement in molecular mechanisms of saliva secretion and diseases offered new avenues for therapeutic approaches, including drugs, gene therapy and tissue engineering. As such, AQP5 represents a potential therapeutic target in different strategies for the treatment of xerostomia.
PMID: 32630469 [PubMed – in process]
PMID:
PubMed:32630469
DATE FOUND:
07/08/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32630469?dopt=Abstract
Characterization of antiapoptotic microRNAs in primary Sjögren’s syndrome: potential targets for the treatment of pSS
https://onlinelibrary.wiley.com/doi/abs/10.1002/cbf.3569
https://www.ncbi.nlm.nih.gov/pubmed/32575162?dopt=Abstract
TITLE:
Characterization of antiapoptotic microRNAs in primary Sjögren’s syndrome.
DESCRIPTION:
Characterization of antiapoptotic microRNAs in primary Sjögren’s syndrome.
Cell Biochem Funct. 2020 Jun 23;:
Authors: Yang Y, Hou Y, Li J, Zhang F, Du Q
Abstract
During the development of primary Sjögren’s syndrome (pSS), aberrant expression of autoantigen is a hallmark event. To explore the regulation of autoantigen tripartite motif containing 21 (Ro/SSA, TRIM21), microRNA profiling was performed in our previous study. In which, two TRIM21-targeting microRNAs were identified, namely miR-1207-5p and miR-4695-3p. To further pursue their roles in the development of pSS, assays were performed with cultured human submandibular gland (HSG) cells, and salivary gland tissues. Results showed that transfection of miR-1207-5p or miR-4695-3p mimics down-regulated not only the expression of TRIM21, but also the levels of pro-apoptotic genes B cell lymphoma 2 associated X (BAX), Caspase 9 (CASP-9) and Caspase 8 (CASP-8). This finally led to antiapoptotic phenotypes in HSG cells. Consistent with the antiapoptotic activity, transfection of microRNA inhibitors up-regulated the expression of TRIM21 and led to a pro-apoptotic phenotype. These therefore propose miR-1207-5p and miR-4695-3p as two antiapoptotic microRNAs functioning through apoptosis pathway. Supporting this speculation, assays performed with salivary gland tissues revealed down-regulation of miR-1207-5p and miR-4695-3p, as well as up-regulation of TRIM21 and pro-apoptotic CASP-8 gene in pSS samples. SIGNIFICANCE OF THE STUDY: For pSS patients, apoptosis of acinar and ductal epithelial cells has been proposed to be a potential mechanism that impairs the secretion of salivary glands. In our study, two autoantigen-targeting microRNAs were characterized as antiapoptotic microRNAs functioning through apoptosis pathway, which may be potential targets for the treatment of pSS.
PMID: 32575162 [PubMed – as supplied by publisher]
PMID:
PubMed:32575162
DATE FOUND:
06/24/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32575162?dopt=Abstract
Identification of novel genes associated with dysregulation of B cells in patients with primary Sjögren’s syndrome
https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02248-2
Research article
Open Access
Published: 22 June 2020
Identification of novel genes associated with dysregulation of B cells in patients with primary Sjögren’s syndrome
Abstract
Background
The aim of this study was to identify the molecular mechanism of dysregulation of B cell subpopulations of primary Sjögren’s syndrome (pSS) at the transcriptome level.Methods
We enrolled patients with pSS (n = 6) and healthy controls (HCs) (n = 6) in the discovery cohort using microarray and pSS (n = 14) and HCs (n = 12) in the validation cohort using quantitative PCR (qPCR). Peripheral B cells acquired from these subjects were separated by cell sorting into four subsets: CD38−IgD+ (Bm1), CD38+IgD+ (naive B cells), CD38highIgD+ (pre-germinal centre B cells) and CD38±IgD− (memory B cells). We performed differentially expressed gene (DEG) analysis and weighted gene co-expression network analysis (WGCNA).Results
Expression of the long non-coding RNA LINC00487 was significantly upregulated in all B cell subsets, as was that of HLA and interferon (IFN) signature genes. Moreover, the normalized intensity value of LINC00487 significantly correlated with the disease activity score of all pSS B cell subsets. Studies of human B cell lines revealed that the expression of LINC00487 was strongly induced by IFNα. WGCNA revealed six gene clusters associated with the B cell subpopulation of pSS. Further, SOX4 was identified as an inter-module hub gene.Conclusion
Our transcriptome analysis revealed key genes involved in the dysregulation of B cell subpopulations associated with pSS.
Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases including Sjögren syndrome (SjS)
https://link.springer.com/article/10.1007%2Fs12016-020-08798-2
https://www.ncbi.nlm.nih.gov/pubmed/32557263?dopt=Abstract
TITLE:
Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.
DESCRIPTION:
Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.
Clin Rev Allergy Immunol. 2020 Jun 17;:
Authors: Jiang J, Zhao M, Chang C, Wu H, Lu Q
Abstract
Type I interferons (IFN-Is) are a very important group of cytokines that are produced by innate immune cells but also act on adaptive immune cells. IFN-Is possess antiviral, antitumor, and anti-proliferative effects, as well are associated with the initiation and maintenance of autoimmune disorders. Studies have shown that aberrantly expressed IFN-Is and/or type I IFN-inducible gene signatures in the serum or tissues of patients with autoimmune disorders are linked to their pathogenesis, clinical manifestations, and disease activity. Type I interferonopathies with mutations in genes impacting the type I IFN signaling pathway have shown symptoms and characteristics similar to those of systemic lupus erythematosus (SLE). Furthermore, both interventions in animal models and clinical trials of therapies targeting the type I IFN signaling pathway have shown efficacy in the treatment of autoimmune diseases. Our review aims to summarize the functions and targeted therapies (as well as clinical trials) of IFN-Is in both adult and pediatric autoimmune diseases, such as SLE, pediatric SLE (pSLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), Sjögren syndrome (SjS), and systemic sclerosis (SSc), discussing the potential abnormal regulation of transcription factors and epigenetic modifications and providing a potential mechanism for pathogenesis and therapeutic strategies for future clinical use.
PMID: 32557263 [PubMed – as supplied by publisher]
PMID:
PubMed:32557263
DATE FOUND:
06/20/20 06:04AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32557263?dopt=Abstract
How the Hydroxychloroquine (HCQ) Shortage Highlights Sjogren’s Neglect
https://www.sjogrensadvocate.com/post/hcq-i-the-shortage
How the hydroxychloroquine (HCQ) shortage highlights Sjogren’s neglect
Updated: 4 hours ago
Association of salivary inflammatory biomarkers with primary Sjögren’s syndrome
https://onlinelibrary.wiley.com/doi/abs/10.1111/jop.13070
https://www.ncbi.nlm.nih.gov/pubmed/32538490?dopt=Abstract
TITLE:
Association of salivary inflammatory biomarkers with primary Sjögren’s syndrome.
DESCRIPTION:
Related Articles
Association of salivary inflammatory biomarkers with primary Sjögren’s syndrome.
J Oral Pathol Med. 2020 Jun 15;:
Authors: Moreno-Quispe LA, Serrano J, Virto L, Sanz M, Ramírez L, Fernández-Castro M, Hernández G, López-Pintor RM
Abstract
BACKGROUND: Primary Sjogren’s syndrome (pSS) is an autoimmune disease that leads to salivary and lacrimal gland dysfunction. The adaptive immune response associated with T helper-2 lymphocytes appears to be altered in these patients. Therefore, the objective of this study was to determine the salivary levels of IL-6, 5 and 4 in patients with pSS when compared to a healthy control (HC) group. The secondary objectives were to study whether ILs levels in pSS patients were associated with salivary flow, patient-reported outcomes (PROMs) for xerostomia and oral health quality of life (OHIP-14), pSS classification criteria and presence of extraglandular manifestations.
METHODS: A case-control study was conducted in 36 patients with pSS and 35 HCs. Cytokine levels were measured using high-sensitivity multiplex map human immunoassays. Unstimulated and stimulated whole saliva were collected and patients filled out questionnaires. The U-Mann-Whitney test, chi-squared test and Spearman correlation test were used.
RESULTS: IL-6 was significantly higher in pSS patients than in HCs (p=0.0001). IL-6 was significantly higher in pSS patients with a positive salivary gland biopsy (p=0.04), whole stimulated saliva hyposalivation (p=0.02) and presence of musculoskeletal disorders (p=0.03). There was a non-significant positive correlation between IL-6 levels and PROMs for xerostomia (r=0.31; p=0.06) and OHIP-14 (r=0.07; p=0.68) in pSS patients. Levels of IL-4 and IL-5 were not detected in both pSS and HCs patients.
CONCLUSIONS: Salivary IL-6 levels are significantly associated with pSS patients and therefore, it is hypothesized that this biomarker may be useful in the diagnosis and follow-up of this disease.
PMID: 32538490 [PubMed – as supplied by publisher]
PMID:
PubMed:32538490
DATE FOUND:
06/17/20 06:18AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32538490?dopt=Abstract
Total glucosides of paeony (TGP) alleviates constipation and intestinal inflammation in mice induced by Sjögren’s syndrome
https://www.sciencedirect.com/science/article/abs/pii/S0378874120314264?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/32525066?dopt=Abstract
TITLE:
Total glucosides of paeony (TGP) alleviates constipation and intestinal inflammation in mice induced by Sjögren’s syndrome.
DESCRIPTION:
Total glucosides of paeony (TGP) alleviates constipation and intestinal inflammation in mice induced by Sjögren’s syndrome.
J Ethnopharmacol. 2020 Jun 07;:113056
Authors: Liu G, Wang Z, Li X, Liu R, Li B, Huang L, Chen Y, Zhang C, Zhang H, Li Y, Chen Y, Yin H, Fang W
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Sjögren’s syndrome (SS) is an autoimmune disease and can cause gastrointestinal disorders such as constipation and intestinal inflammation. As a kind of medicinal material, Paeonia lactiflora Pall has a variety of pharmacological effects, and it is also an indispensable component in many pharmaceutical preparations, which has been widely concerned by the medical and pharmaceutical circles. Total glucosides of paeony (TGP) is a mixture of biologically active compounds extracted from the root of Paeonia lactiflora Pall and has therapeutic effects on a variety of autoimmune diseases.
AIM OF THE STUDY: To investigate the therapeutic effect of TGP on constipation and intestinal inflammation in mice modeled by SS, and to provide a basis for clinical research.
MATERIALS AND METHODS: The SS model was set up by submandibular gland (SMG) immune induction method and then treated with TGP for 24 weeks. The fecal characteristics were observed and the fecal number and moisture content were measured. Colonic pathology was observed by H&E staining. The levels of serum P substance (SP), vasoactive intestinal peptide (VIP), interleukin (IL)-1β, tumor necrosis factor (TNF)-α, nuclear factor (NF)-κB, nitric oxide (NO), and nitric oxide synthase (NOS) were determined by enzyme linked immunosorbent assay (ELISA) and microplate method, respectively. Reverse transcription polymerase chain reaction (RT-PCR) was employed to analyze the mRNA expression of c-kit and stem cell factor (SCF) in colon.
RESULTS: Compared with the model group, the dry and rough condition of the feces was improved, and the fecal gloss, number and moisture content significantly increased after the administration of TGP capsules. Meanwhile, TGP treatment improved colonic pathological damage, inhibited the serum concentrations of NO, NOS, IL-1β, TNF-α, NF-κB and SP, increased serum VIP concentration, and up-regulated mRNA expression of SCF and c-kit in colon.
CONCLUSIONS: TGP could obviously attenuate SS-mediated constipation and intestinal inflammation in mice by acting on some intestinal motility related factors and inflammatory factors.
PMID: 32525066 [PubMed – as supplied by publisher]
PMID:
PubMed:32525066
DATE FOUND:
06/12/20 06:14AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32525066?dopt=Abstract
Fecal Microbial Transplant (FMT) for Sjogren’s Syndrome [Completed]
https://www.clinicaltrials.gov/ct2/show/NCT03926286?type=Intr&cond=Sjogren%27s+Syndrome&sort=nwst&draw=2&rank=9
Fecal Microbial Transplant (FMT) for Sjogrens Syndrome
Study Description
Go to sections
Brief Summary:
This is an open label study to evaluate the effect of Fecal Microbiota Transplantation (FMT) on the gut microbiome and Systemic parameters.
Condition or disease Intervention/treatment Phase
Sjogren’s Syndrome
Drug: FMP-30
Phase 1
Study Design
Go to sections
Study Type : Interventional
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fecal Microbial Transplant for Sjogrens Syndrome
Actual Study Start Date : April 15, 2019
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : December 1, 2021
The 2020 Sjögren’s Foundation National Patient Conference (June 26 & June 27, 2020) is going Virtual
https://www.sjogrens.org/news/2020/the-2020-sjogrens-foundation-national-patient-conference-is-going-virtual
The 2020 Sjögren’s Foundation National Patient Conference is going Virtual!
June 26 & June 27, 2020
Safety and Efficacy of VAY736 in Patients With Primary Sjogren’s Syndrome (pSS)
https://www.clinicaltrials.gov/ct2/show/NCT02962895
Safety and Efficacy of VAY736 in Patients With Primary Sjogren’s Syndrome (pSS)
Brief Summary:
This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters
Condition or disease Intervention/treatment Phase
Primary Sjogren Syndrome
Biological: VAY736
Other: Placebo
Phase 2
Study Design
Go to sections
Study Type : Interventional (Clinical Trial)
Actual Enrollment : 195 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren’s Syndrome (pSS)
Actual Study Start Date : June 27, 2017
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2020
Efficacy of Belimumab in Primary Sjögren’s Syndrome: A Systematic Review
https://www.sciencedirect.com/science/article/pii/S1699258X20300760?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/32451263?dopt=Abstract
TITLE:
Efficacy of Belimumab in Primary Sjögren’s Syndrome: A Systematic Review.
DESCRIPTION:
Related Articles
Efficacy of Belimumab in Primary Sjögren’s Syndrome: A Systematic Review.
Reumatol Clin. 2020 May 22;:
Authors: Álvarez-Rivas N, Sang-Park H, Díaz Del Campo P, Fernández-Castro M, Corominas H, Andreu JL, Navarro-Compán V
Abstract
OBJECTIVE: To evaluate the efficacy and safety of belimumab in patients with Primary Sjögren’s syndrome (pSS).
METHODS: The search included manuscripts assessing the efficacy or safety of belimumab in patients with pSS (American-European Consensus Criteria 2002) published between 2004 and 2017 in MEDLINE, EMBASE or Cochrane databases. Two reviewers independently selected the articles, extracted data and evaluated the quality of the evidence following Scottish Intercollegiate Guidelines Network (SIGN) recommendation grades.
RESULTS: Out of 135 citations, only 3 articles were included. All of them publishing results from the same study at different time points including 28 patients. At week 28 improvement was reported for visual analogue scale (VAS) dryness score and glandular manifestations in 37% and 77% of patients, respectively, which persisted at week 52 (W52). Belimumab was well tolerated and safely administered.
CONCLUSION: Published evidence to determine the efficacy of belimumab in pSS is limited. Belimumab seems to be effective to reduce systemic activity, parotid enlargement, lymphadenopathies, articular manifestation and B cell biomarkers.
PMID: 32451263 [PubMed – as supplied by publisher]
PMID:
PubMed:32451263
DATE FOUND:
05/27/20 06:20AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32451263?dopt=Abstract
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren’s Syndrome
https://www.clinicaltrials.gov/ct2/show/NCT04035668
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren’s Syndrome (LOUiSSe)
Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren’s Syndrome
https://www.mdpi.com/2077-0383/9/5/1482
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290729/
https://www.ncbi.nlm.nih.gov/pubmed/32423153?dopt=Abstract
TITLE:
Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren’s Syndrome.
DESCRIPTION:
Related Articles
Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren’s Syndrome.
J Clin Med. 2020 May 14;9(5):
Authors: Butryn M, Neumann J, Rolfes L, Bartels C, Wattjes MP, Mahmoudi N, Seeliger T, Konen FF, Thiele T, Witte T, Meuth SG, Skripuletz T, Pawlitzki M
Abstract
OBJECTIVE: To identify radiological and laboratory hallmarks in patients with primary Sjögren’s syndrome (pSS) presenting with spinal cord involvement.
METHODS: Clinical and laboratory routine parameters were analyzed in a retrospective multicenter case series of four patients who developed myelitis associated with pSS. Serological and cerebrospinal fluid (CSF) measurements of pSS associated anti-SSA(Ro)-antibodies were initiated, and CSF neurofilament light chain (NFL) levels were assessed. NFL values were compared with results from 15 sex- and age-matched healthy controls. Radiological assessment was performed using multi-sequence spinal cord magnetic resonance imaging.
RESULTS: Three of the four patients initially developed neurological signs suggestive of myelitis and were subsequently diagnosed with pSS. All patients presented a longitudinal spinal T2-hyperintense lesion in the cervical spinal cord, whereas only two patients showed pleocytosis and oligoclonal bands in the CSF. Median (range) CSF-NFL levels were significantly elevated in patients compared to controls (6672 pg/mL (621-50000) vs. 585 pg/mL (357-729), p = 0.009). One patient showed sustained, highly increased NFL levels (50000 pg/mL) in the initial assessment when radiological signs of axonal injury were still absent. Anti-SSA(Ro)-antibodies were found in the serum of three patients, while two patients additionally presented intrathecal anti-SSA(Ro)-antibody production. Elevated CSF-NFL levels and intrathecal synthesis of anti-SSA(Ro)-antibodies were associated with a relapsing and treatment-resistant disease course.
CONCLUSION: Inflammatory spinal cord lesions associated with pSS are a rare but serious disease leading to severe disability. NFL and anti-SSA(Ro)-antibodies in CSF might serve as prognostic biomarkers and should be routinely assessed in patients with pSS.
PMID: 32423153 [PubMed]
PMID:
PubMed:32423153
DATE FOUND:
05/20/20 08:41AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32423153?dopt=Abstract
Immunobiology of T Cells in Sjögren’s Syndrome: summary of research progress to provide insights for clinical treatment
https://link.springer.com/article/10.1007/s12016-020-08793-7
https://www.ncbi.nlm.nih.gov/pubmed/32390096?dopt=Abstract
TITLE:
Immunobiology of T Cells in Sjögren’s Syndrome.
DESCRIPTION:
Immunobiology of T Cells in Sjögren’s Syndrome.
Clin Rev Allergy Immunol. 2020 May 11;:
Authors: Yao Y, Ma JF, Chang C, Xu T, Gao CY, Gershwin ME, Lian ZX
Abstract
Sjögren’s syndrome (SjS) is a systemic autoimmune disease marked by xerostomia (dry mouth), keratoconjunctivitis sicca (eye dryness), and other systematic disorders. Its pathogenesis involves an inflammatory process that is characterized by lymphocytic infiltration into exocrine glands and other tissues. Although the development of ectopic lymphoid tissue and overproduction of autoantibodies by hyperactive B cells suggest that they may promote SjS development, treatment directed towards them fails to induce significant laboratory or clinical improvement. T cells are overwhelming infiltrators in most phases of the disease, and the involvement of multiple T cell subsets of suggests the extraordinary complexity of SjS pathogenesis. The factors, including various cellular subtypes and molecules, regulate the activation and suppression of T cells. T cell activation induces inflammatory cell infiltration, B cell activation, tissue damage, and metabolic changes in SjS. Knowledge of the pathways that link these T cell subtypes and regulation of their activities are not completely understood. This review comprehensively summarizes the research progress and our understanding of T cells in SjS, including CD4+ T cells, CD8+ TRM cells, and innate T cells, to provide insights into for clinical treatment.
PMID: 32390096 [PubMed – as supplied by publisher]
PMID:
PubMed:32390096
DATE FOUND:
05/12/20 06:07AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32390096?dopt=Abstract
Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome
https://www.biospace.com/article/releases/wize-pharma-completes-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogren-s-syndrome/
Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome
Clinical significance of progranulin correlated with serum soluble Oxford 40 ligand in primary Sjögren’s syndrome: PGRN and sOX40L serve as an important markers of pSS
https://journals.lww.com/md-journal/fulltext/2020/05010/clinical_significance_of_progranulin_correlated.31.aspx
Clinical significance of progranulin correlated with serum soluble Oxford 40 ligand in primary Sjögren’s syndrome
PGRN and sOX40L serve as an important markers of pSS
Targeted Approach for Tackling Sjögren’s Syndrome – Small molecules restore salivary function in mice
https://www.nidcr.nih.gov/news-events/nidcr-news/targeted-approach-tackling-sjogrens-syndrome
Targeted Approach for Tackling Sjögren’s Syndrome
Small molecules restore salivary function in mice
Fibromyalgia, Sjogren’s & Depression: Linked?
https://www.tandfonline.com/doi/abs/10.1080/00325481.2020.1758426?journalCode=ipgm20
https://www.ncbi.nlm.nih.gov/pubmed/32314938?dopt=Abstract
TITLE:
Fibromyalgia, Sjogren’s & Depression: Linked?
DESCRIPTION:
Fibromyalgia, Sjogren’s & Depression: Linked?
Postgrad Med. 2020 Apr 21;:
Authors: Loganathan M, Ladani A, Lippmann S
Abstract
Health care has become increasingly fragmented, partly due to advancing medical technology. Patients are often managed by various specialty teams when presenting with symptoms that could be manifestations of different diseases. Approximately one third of them are referred to specialists, at over half for outpatient appointments.1 Fatigue, pain, depression, dry mouth, headaches, and arthralgia are common complaints and frequently require referral to specialist physicians. Differential diagnoses include fibromyalgia (FM), Sjogren’s syndrome (SS), and depression. Evaluations involve various sub-specialist especially physicians like those practicing pain management, rheumatology, and psychiatry.Thresholds for referring vary. Patients sometime feel lost in a “medical maze”. Disagreement is frequent between specialties regarding management.1,2 Each discipline has its own diagnostic and treatment protocols and there is little consensus about shared decision-making. Communication between doctors could improve continuity. There are many differences and similarities in the pathophysiology, symptomatology, diagnosis, and treatment of fibromyalgia, Sjogren’s syndrome, and depression. Understanding the associations between fibromyalgia, Sjogren’s syndrome and depression should improve clinical outcome via a common holistic approach.
PMID: 32314938 [PubMed – as supplied by publisher]
PMID:
PubMed:32314938
DATE FOUND:
04/22/20 06:18AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32314938?dopt=Abstract
Cysteine cathepsins as therapeutic targets in inflammatory diseases
https://www.tandfonline.com/doi/abs/10.1080/14728222.2020.1746765
Cysteine cathepsins as therapeutic targets in inflammatory diseases
Matej Vizovišek,Eva Vidak,Urban Javoršek,Georgy Mikhaylov,Andreja Bratovš &Boris Turk
Pages 573-588 | Received 23 Dec 2019, Accepted 20 Mar 2020, Accepted author version posted online: 31 Mar 2020, Published online: 06 Apr 2020
Download citation https://doi.org/10.1080/14728222.2020.1746765 CrossMark LogoCrossMark
Rebamipide for the Treatment of Xerostomia (Dry Mouth) in Sjögren Syndrome
https://clinicaltrials.gov/ct2/show/NCT01759108?type=Intr
https://clinicaltrials.gov/ct2/show/NCT01759108?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F17%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
Rebamipide AND Sjögren Syndrome
DESCRIPTION:
Condition: Improving Symptoms of Dry Mouth in Sjőgren’s Syndrome
Intervention: Drug: Rebamipide
Sponsor: University of Alexandria
Recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT01759108
FIRST POSTED:
Wed, 02 Jan 2013 12:00:00 EST
LAST UPDATE POSTED:
03/31/20 09:29AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT01759108?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F17%2F2020&lupd_d=14&sort=nwst
JAK Inhibitors: Prospects in Connective Tissue Diseases including Sjögren’s Syndrome
https://link.springer.com/article/10.1007/s12016-020-08786-6
https://www.ncbi.nlm.nih.gov/pubmed/32222877?dopt=Abstract
TITLE:
JAK Inhibitors: Prospects in Connective Tissue Diseases.
DESCRIPTION:
Related Articles
JAK Inhibitors: Prospects in Connective Tissue Diseases.
Clin Rev Allergy Immunol. 2020 Mar 28;:
Authors: You H, Xu D, Zhao J, Li J, Wang Q, Tian X, Li M, Zeng X
Abstract
The dysregulation of the JAK-STAT pathway is associated with various immune disorders. Four JAK inhibitors have been approved for rheumatoid arthritis (RA), and numerous JAK inhibitors are currently being tested in phase II and III trials for the treatment of various autoimmune inflammatory diseases. In this narrative review, we elucidate the involvement of the JAK-STAT signaling pathway in the pathogenesis of connective tissue diseases (CTDs). We also discuss the efficacy of the first- and second-generation JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib, filgotinib, upadacitinib, solcitinib, itacitinib, decernotinib, R333, and pf-06651600) for CTDs including RA, systemic lupus erythematosus, dermatomyositis, systemic sclerosis, Sjögren’s syndrome, and vasculitis, based on laboratory and clinical research findings. JAK inhibitors have great potential for the treatment of various CTDs by reducing multiple cytokine production and suppressing inflammation, with the advantages of rapid onset in an oral formulation and decreased corticosteroid dependence and the associated adverse events, especially in refractory cases. We also highlight the safety of novel JAK inhibitors, which can cause opportunistic infections, especially viral infections. Being a very recent therapeutic option, information regarding the safety of JAK inhibitors during pregnancy and for pediatric use is limited. However, it is recommended that JAK inhibitors should be avoided in pregnant and breastfeeding women. More clinical data, especially on highly selective inhibitors, are required to judge the efficacy and safety of JAK inhibition in CTDs.
PMID: 32222877 [PubMed – as supplied by publisher]
PMID:
PubMed:32222877
DATE FOUND:
03/31/20 06:06AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32222877?dopt=Abstract
Abatacept Fails Clinical Trial for Sjögren’s Syndrome
https://www.rheumatologynetwork.com/sjogrens-syndrome/abatacept-fails-clinical-trial-sjgrens-syndrome
Abatacept Fails Clinical Trial for Sjögren’s Syndrome
Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome
https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome
DESCRIPTION:
Condition: Primary Sjögren Syndrome
Intervention: Drug: Ustekinumab
Sponsor: University of Rochester
Not yet recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT04093531
FIRST POSTED:
Wed, 18 Sep 2019 12:00:00 EDT
LAST UPDATE POSTED:
10/22/19 07:00AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst
Total glucosides of paeony (TGP) alleviates Sjogren’s syndrome through inhibiting inflammatory responses in mice
https://www.sciencedirect.com/science/article/abs/pii/S0944711320300362?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/32402913?dopt=Abstract
TITLE:
Total glucosides of paeony (TGP) alleviates Sjogren’s syndrome through inhibiting inflammatory responses in mice.
DESCRIPTION:
Total glucosides of paeony (TGP) alleviates Sjogren’s syndrome through inhibiting inflammatory responses in mice.
Phytomedicine. 2020 Mar 06;71:153203
Authors: Li B, Liu G, Liu R, He S, Li X, Huang L, Wang Z, Li Y, Chen Y, Yin H, Fang W
Abstract
BACKGROUND: Sjogren’s syndrome (SS) is an inflammatory autoimmune disease whose etiology is complicated. Total glucosides of paeony (TGP) has a variety of pharmacological effects.
PURPOSE: To evaluate the therapeutic effects of TGP on SS in mice and anti-inflammatory mechanism.
STUDY DESIGN: SS animal model was developed from C57BL/6J mice through immunological induction (SS mice) and NOD/ShiltJNju (NOD) mice. Inflammatory cytokines and other related indicators were measured.
METHODS: TGP (720, 360, 180 mg/kg) was intragastrically administered for 6 or 16 weeks for SS mice and NOD mice, respectively. Average food and water intake, average body weight, saliva flow, submandibular gland (SMG) and spleen index, and SMG pathology were measured. ELISA was used to evaluate serum inflammatory cytokines in SS mice and autoantigens in NOD mice. Real-time PCR, Western blot and Luminex liquid suspension chip assay were applied to analyze SMG inflammatory cytokines mRNA and protein expression of NOD mice.
RESULTS: Compared with SS mice, TGP treatment improved SMG pathological damage. TGP (720 mg/kg) treatment increased saliva flow, and reduced organ indexes and serum IL-6 and IFN-γ concentration. TGP (360 mg/kg) treatment decreased serum IFN-γ concentration. TGP (180 mg/kg) treatment for 6 weeks decreased average body weight. Compared with NOD mice, TGP treatment increased saliva flow from 9 to 15 weeks, decreased body weight, and alleviated pathological damage of SMG after 2 and 16 weeks. After 2 weeks of administration, TGP treatment inhibited serum concentration of SSB/La, SSA/Ro and α-fodrin, decreased TNF-α, IL-1β and IFN-γ in SMG, and down-regulated protein expressions of BAFF and IL-17A and mRNA expressions of BAFF, TNF-α, IL-17A, CXCL9 and CXCL13 in SMG. After 8 weeks of administration, TGP treatment decreased the concentration of α-fodrin in serum, TNF-α and IL-6 in SMG, and down-regulated mRNA expressions of IL-17A, TNF-α, CXCL9, CXCL13 and BAFF and protein expressions of IL-17A and BAFF in SMG. After 16 weeks of administration, TGP treatment reduced serum SSA/Ro, SSB/La and α-fodrin concentration, and decreased BAFF protein expression and TNF-α, CXCL9, CXCL13, IL-17A, and BAFF mRNA expressions.
CONCLUSION: TGP has a certain therapeutic effect on SS mice and NOD mice through inhibiting inflammatory responses.
PMID: 32402913 [PubMed – as supplied by publisher]
PMID:
PubMed:32402913
DATE FOUND:
05/14/20 06:22AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32402913?dopt=Abstract
Depletion of ID3 enhances mesenchymal stem cells therapy by targeting BMP4 in Sjögren’s syndrome
https://www.nature.com/articles/s41419-020-2359-6
https://www.ncbi.nlm.nih.gov/pubmed/32139667?dopt=Abstract
TITLE:
Depletion of ID3 enhances mesenchymal stem cells therapy by targeting BMP4 in Sjögren’s syndrome.
DESCRIPTION:
Related Articles
Depletion of ID3 enhances mesenchymal stem cells therapy by targeting BMP4 in Sjögren’s syndrome.
Cell Death Dis. 2020 Mar 05;11(3):172
Authors: Hu L, Xu J, Wu T, Fan Z, Sun L, Liu Y, Li Y, Zhang C, Wang J, Ding Y, Wang S
Abstract
Mesenchymal stem cell (MSCs) transplantation has been used to treat Sjögren’s syndrome (SS) based on the immunoregulatory properties of MSCs. However, the effectiveness need improving and its underlying intrinsic mechanisms remain largely unknown. Here, we show that Id3 is upregulated in bone marrow-derived MSCs (BMMSCs) isolated from NOD/ShiLtJ mice, a widely used SS model, compared with ICR mice as control, suggesting that it functions in SS development and therapy. Transplantation of Id3-deficient BMMSCs rescues salivary gland function more effective than wild-type BMMSCs in NOD/ShiLtJ mice. Mechanistically, we show that ID3 negatively regulated BMP4 expression by preventing binding of basic helix-loop-helix protein E2A to the promoter of the Bmp4 gene. BMP4 in turn promoted PGE2 production in MSCs, and exhibited enhanced suppressive activities of T-cell proliferation and Th1 differentiation. Importantly, BMMSCs from SS patients showed significantly lower BMP4 and PGE2 expression than those from healthy individuals. Taken together, our findings revealed the targeting Id3 may be therapeutically useful for improving MSC immunoregulation and effectiveness of MSCs therapy for SS.
PMID: 32139667 [PubMed – in process]
PMID:
PubMed:32139667
DATE FOUND:
03/07/20 06:02AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32139667?dopt=Abstract
Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren’s syndrome
https://www.sciencedirect.com/science/article/pii/S1521694220300012?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/32067925?dopt=Abstract
TITLE:
Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren’s syndrome.
DESCRIPTION:
Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren’s syndrome.
Best Pract Res Clin Rheumatol. 2020 Feb 15;:101485
Authors: van den Hoogen LL, van Laar JM
Abstract
Targeted therapies using biological disease-modifying antirheumatic drugs (bDMARDs) and small molecule synthetic drugs have revolutionized rheumatological practice. Initially developed for the treatment of immune arthritis (rheumatoid arthritis, psoriatic arthritis, and spondylarthritis), both bDMARDs and small molecule synthetic drugs are now increasingly entering the space of connective tissue disease (CTD) treatment. Recent clinical trial data in systemic sclerosis (SSc) have been particularly encouraging with positive effects on outcomes having been observed with nintedanib preventing the decline of lung function in patients with SSc-related interstitial lung disease. Randomized trials targeting B-cells by rituximab in primary Sjogren’s syndrome have led to mixed results. Novel strategies to target B-cells in primary Sjögren’s syndrome including ianalumab and belimumab are underway and will hopefully result in clear treatment effects. Inflammatory idiopathic myositis (polymyositis (PM) and dermatomyositis (DM)) and antiphospholid syndrome are proving to be more difficult to tackle but are nonetheless the subject of ongoing studies. To what extent new compounds can replace more traditional immunosuppressive drugs remains to be determined, but if the experience in immune arthritis has taught us anything it is that combination therapy may be the way to go.
PMID: 32067925 [PubMed – as supplied by publisher]
PMID:
PubMed:32067925
DATE FOUND:
02/19/20 08:39AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32067925?dopt=Abstract
Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled
Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled
Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled
Wize Pharma Completes Patient Enrollment In Phase 4 Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome
https://www.prnewswire.com/news-releases/wize-pharma-completes-patient-enrollment-in-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome-300990264.html
Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome
– Topline Results Expected Q2 2020
– Study designed to support approval pathway in the U.S. and other major markets
Jan 21, 2020, 09:00 ET
HOD HASHARON, Israel, Jan. 21, 2020 /PRNewswire/ — Wize Pharma, Inc. (OTCQB: WIZP) (“Wize”), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed enrolment in its Phase IV clinical trial of its eye drop formula to evaluate the efficacy of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome.
Mechanisms of Disease in Sjögren Syndrome-New Developments and Directions
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013496/
https://www.ncbi.nlm.nih.gov/pubmed/31963817?dopt=Abstract
TITLE:
Mechanisms of Disease in Sjögren Syndrome-New Developments and Directions.
DESCRIPTION:
Related Articles
Mechanisms of Disease in Sjögren Syndrome-New Developments and Directions.
Int J Mol Sci. 2020 Jan 19;21(2):
Authors: de Paiva CS, Pflugfelder SC
Abstract
Sjögren Syndrome (SS) is an autoimmune disease that affects the exocrine glands, mainly salivary and lacrimal glands […].
PMID: 31963817 [PubMed – indexed for MEDLINE]
PMID:
PubMed:31963817
DATE FOUND:
10/08/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31963817?dopt=Abstract
Potential Sjogren’s Therapy LOU064 Shows Promise in Early Lab Studies, Healthy Volunteers
Potential Sjogren’s Therapy LOU064 Shows Promise in Early Lab Studies, Healthy Volunteers
Potential Sjogren’s Therapy LOU064 Shows Promise in Early Lab Studies, Healthy Volunteers
Alleviating effect of CP-25 in antigen-induced experimental Sjögren’s syndrome by modulating B lymphocyte migration via CXCR5-GRK2-ERK/p38 signaling pathway
https://www.sciencedirect.com/science/article/pii/S156757691932613X?via%3Dihub
Alleviating effect of paeoniflorin-6′-O-benzene sulfonate in antigen-induced experimental Sjögren’s syndrome by modulating B lymphocyte migration via CXCR5-GRK2-ERK/p38 signaling pathway
Primary Sjogren’s syndrome: a great masquerader
https://casereports.bmj.com/content/12/12/e231802.full
https://casereports.bmj.com/content/12/12/e231802
https://www.ncbi.nlm.nih.gov/pubmed/31888893?dopt=Abstract
TITLE:
Primary Sjogren’s syndrome: a great masquerader.
DESCRIPTION:
Related Articles
Primary Sjogren’s syndrome: a great masquerader.
BMJ Case Rep. 2019 Dec 29;12(12):
Authors: Kumar N, Surendran D, Srinivas BH, Bammigatti C
Abstract
A 41-year-old woman presented with paresthesia and inability to walk for 7 days. She had history of fatigue, polyarthralgia and difficulty in swallowing food for the last 1 year. She became edentulous over the last 5 years and wore dentures for the same. She appeared pale, emaciated and had oral thrush. She had areflexic quadriparesis with weakness more in lower limbs compared with upper limbs. With the initial diagnosis of Guillian-Barre syndrome, she was given five cycles of plasmapheresis following which there was a significant improvement in power. Sjogren’s syndrome was suspected based on edentulous state in a middle-aged woman with multisystem involvement. Evaluation with Schirmer’s test, parotid scintigraphy and labial minor salivary gland biopsy confirmed the diagnosis. She was treated with steroids following which a dramatic improvement in haemoglobin and total leucocyte count was noted. We report a varied presentation of primary Sjogren’s syndrome.
PMID: 31888893 [PubMed – indexed for MEDLINE]
PMID:
PubMed:31888893
DATE FOUND:
05/16/20 06:06AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31888893?dopt=Abstract
A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren’s syndrome
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294338/
https://www.sciencedirect.com/science/article/pii/S0168365918306059?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/30359668?dopt=Abstract
TITLE:
A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren’s syndrome.
DESCRIPTION:
Related Articles
A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren’s syndrome.
J Control Release. 2018 12 28;292:183-195
Authors: Guo H, Lee C, Shah M, Janga SR, Edman MC, Klinngam W, Hamm-Alvarez SF, MacKay JA
Abstract
As a potent macrolide immunosuppressant, cyclosporine A (CsA) is used to treat multiple autoimmune diseases, including non-autoimmune and autoimmune-mediated dry eye disease, rheumatoid arthritis and psoriasis. Despite its potency, CsA has poor solubility, poor bioavailability, and can cause serious adverse reactions such as nephrotoxicity and neurotoxicity. To overcome these limitations, we invented a new strategy to carry CsA by fusing its cognate human receptor, cyclophilin A (CypA), to a 73 kDa elastin-like polypeptide (ELP) termed A192 using recombinant protein expression. Derived from human tropoelastin, ELPs are characterized by the ability to phase separate above a temperature that is a function of variables including concentration, molecular weight, and hydrophobicity. The resultant fusion protein, termed CA192, which assembles into a dimeric species in solution, effectively binds and solubilizes CsA with a Kd of 189 nM, comparable to that of endogenous CypA with a Kd of 35.5 nM. The release profile of CsA from CA192 follows a one phase decay model with a half-life of 957.3 h without a burst release stage. Moreover, CA192-CsA inhibited IL-2 expression induced in Jurkat cells through the calcineurin-NFAT signaling pathway with an IC50 of 1.2 nM, comparable to that of free CsA with an IC50 of 0.5 nM. The intravenous pharmacokinetics of CA192 followed a two-compartment model with a mean residence time of 7.3 h. Subcutaneous administration revealed a bioavailability of 30% and a mean residence time of 15.9 h. When given subcutaneously for 2 weeks starting at 14 weeks in male non-obese diabetic (NOD) mice, a model of autoimmune dacryoadenitis used to study Sjögren’s syndrome (SS), CA192-CsA (2.5 mg/kg, every other day) significantly (p = 0.014) increased tear production relative to CA192 alone. Moreover, CA192 delivery reduced indications of CsA nephrotoxicity relative to free CsA. CA192 represents a viable new approach to deliver this effective but nephrotoxic agent in a modality that preserves therapeutic efficacy but suppresses drug toxicity.
PMID: 30359668 [PubMed – indexed for MEDLINE]
PMID:
PubMed:30359668
DATE FOUND:
10/25/19 05:22PM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/30359668?dopt=Abstract
A213, a RORγt antagonist, improves Sjögren’s syndrome-like sialadenitis through downregulation of CD25
https://onlinelibrary.wiley.com/doi/abs/10.1111/odi.13255
https://www.ncbi.nlm.nih.gov/pubmed/31837283?dopt=Abstract
TITLE:
RORγt antagonist improves Sjögren’s syndrome-like sialadenitis through downregulation of CD25.
DESCRIPTION:
Related Articles
RORγt antagonist improves Sjögren’s syndrome-like sialadenitis through downregulation of CD25.
Oral Dis. 2020 May;26(4):766-777
Authors: Ono Y, Tsuboi H, Moriyama M, Asashima H, Kudo H, Takahashi H, Honda F, Abe S, Kondo Y, Takahashi S, Matsumoto I, Nakamura S, Sumida T
Abstract
OBJECTIVE: We reported previously that T-cell-specific RORγt-transgenic mice under human CD2 promoter (RORγt-Tg mice) developed severe spontaneous Sjögren’s syndrome (SS)-like sialadenitis, induced by RORγt-overexpressing CD4+ T cells and reduced regulatory T cells. The purpose of this study was to clarify the effectiveness and mechanisms of action of A213, a RORγt antagonist, in RORγt-Tg mice with SS-like sialadenitis.
METHODS: Six-week-old RORγt-Tg mice were administered orally of A213 or phosphate-buffered saline every 3 days for 2 weeks. We analyzed saliva volume, histopathology of salivary glands, populations of T cells in splenocytes and cervical lymph nodes (cLNs), and the protein expression levels of CD69 on CD4+ CD25+ Foxp3- and CD4+ CD25+ Foxp3+ cells in cLNs. We also investigated in vitro the potential immunomechanisms of action of A213.
RESULTS: A213 significantly increased saliva volume, reduced mononuclear cell infiltration in salivary glands, and reduced the focus score of sialadenitis. Analysis of the immunomechanisms using cLNs showed A213 significantly reduced the proportion of CD4+ CD25+ /CD4+ T cells and the protein expression levels of CD69 on CD4+ CD25+ Foxp3- cells. In vitro experiments showed that A213 suppressed CD25 expression on CD4+ T cells and reduced IL-2 production from CD4+ T cells derived from RORγt-Tg mice.
CONCLUSION: A213 improves SS-like sialadenitis through the inhibition of CD4+ CD25+ cells in cLNs.
PMID: 31837283 [PubMed – indexed for MEDLINE]
PMID:
PubMed:31837283
DATE FOUND:
08/01/20 06:03AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31837283?dopt=Abstract
Sjögren’s syndrome: Old and new therapeutic targets
https://www.sciencedirect.com/science/article/abs/pii/S0896841119307267
Sjögren’s syndrome: Old and new therapeutic targets
Academy of Athens, Chair Medical Sciences/Immunology, Greece
Received 6 November 2019, Accepted 10 November 2019, Available online 9 December 2019.
LncRNA PVT1 links Myc to glycolytic metabolism upon CD4+ T cell activation and Sjögren’s syndrome-like autoimmune response
https://www.sciencedirect.com/science/article/pii/S0896841119306006?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/31757716?dopt=Abstract
TITLE:
LncRNA PVT1 links Myc to glycolytic metabolism upon CD4+ T cell activation and Sjögren’s syndrome-like autoimmune response.
DESCRIPTION:
Related Articles
LncRNA PVT1 links Myc to glycolytic metabolism upon CD4+ T cell activation and Sjögren’s syndrome-like autoimmune response.
J Autoimmun. 2019 Nov 19;:102358
Authors: Fu J, Shi H, Wang B, Zhan T, Shao Y, Ye L, Wu S, Yu C, Zheng L
Abstract
The hyperproliferation and hyperactivation of CD4+ T cells in salivary gland tissue is a hallmark of Sjögren’s syndrome (SS). However, the role of long noncoding RNAs (lncRNAs) in the pathological process of SS and CD4+ T cell activation has not been fully elucidated. Here, we reported that lncRNA PVT1 was involved in the glycolytic metabolism reprogramming and proliferation upon CD4+ T cell activation. Expression of PVT1 was positively related with CD4+ T cell activation both in SS patients and Ex vivo antigen simulation. Depletion of PVT1 decreased the proliferation of murine CD4+ T cells and Jurkat T cells upon activation. We also showed that expression of the transcription factor Myc is regulated by PVT1 under antigen simulation. Depletion of PVT1 significantly decreased the expression of glycolytic genes, as well as several pivotal glycolytic proteins that were directly transcribed by Myc. Measurement of glucose content and lactate secretion indicated a defected lactate secretion and glucose uptake in PVT1-depleted T cells. Additionally, the real-time extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) measurement also affirmed that PVT1 maintains glycolytic levels, glycolytic capacity under stress and ECAR/OCR ratios during T cell activation. Polarizing assays indicate that PVT1 depletion defected the function of Th1 effector cells as well as down-regulated Myc expression and glycolytic levels. Furthermore, we observed increased glycolytic levels in CD4+ T cells from SS-like NOD/Ltj mice. Treatment with 2-deoxy-d-glucose (2-DG), an inhibitor of glycolysis, significantly decreased the extent of lymphocyte infiltration and CD4+ T cell numbers and attenuated the defect of salivary flow in the lesioned submandibular glands of NOD/Ltj mice. Thus, our study demonstrated that lncRNA PVT1, which was upregulated in the CD4+T cells of SS patients, could maintain the expression of Myc, thus controlling the proliferation and effector functions of CD4+ T cells through regulating the reprogramming of glycolysis. Inhibition of glycolysis could attenuate the proliferation of CD4+ T cells and the SS-like autoimmune response. Our study provides a novel mechanistic function of lncRNA PVT1 in the pathogenesis of SS.
PMID: 31757716 [PubMed – as supplied by publisher]
PMID:
PubMed:31757716
DATE FOUND:
11/24/19 07:36AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31757716?dopt=Abstract
Associations of Anti-Aquaporin 5 Autoantibodies with Features of Sjögren’s Syndrome: Screening may reveal subgroups of SS for targeted therapy
https://www.mdpi.com/2077-0383/8/11/1863
https://www.ncbi.nlm.nih.gov/pubmed/31684196?dopt=Abstract
TITLE:
Associations of Anti-Aquaporin 5 Autoantibodies with Serologic and Histopathological Features of Sjögren’s Syndrome.
DESCRIPTION:
Related Articles
Associations of Anti-Aquaporin 5 Autoantibodies with Serologic and Histopathological Features of Sjögren’s Syndrome.
J Clin Med. 2019 Nov 03;8(11):
Authors: Jeon S, Lee J, Park SH, Kim HD, Choi Y
Abstract
Biomarkers to stratify the complex and heterogeneous phenotypes of Sjogren’s syndrome (SS) are needed. We aimed to validate the prevalence of anti-aquaporin 5 (AQP5) IgG in a non-Korean cohort and to optimize the method to screen the anti-AQP5 IgG. The study cohort included 111 primary SS and 43 non-SS Sjögren’s International Collaborative Clinical Alliance (SICCA) controls that were obtained from the Sjögren’s International Collaborative Clinical Alliance registry, in addition to 35 systemic lupus erythematosus (SLE) and 35 rheumatoid arthritis (RA) phenotypes. Anti-AQP5 IgG was screened by cell-based immunofluorescence cytochemistry (CB-IFC) assay in the absence or presence of epitope peptides, as well as by ELISA using the epitope peptides as coated antigens. Anti-AQP5 IgG specific to an E1 epitope was best at discriminating between SS and non-SS, and the two different methods (CB-IFC and ELISA) presented comparable performance in diagnostic accuracy (0.690 vs. 0.707). Notably, the SLE and RA groups had substantially lower levels of anti-AQP5 IgG than the SS group. In addition, the presence of anti-AQP5_E1 IgG was associated with serologic and histopathological features of SS. In conclusion, a similar prevalence of anti-AQP5 IgG was confirmed in a non-Korean cohort. Screening anti-AQP5 autoantibodies may help to form subgroups of SS for targeted therapy.
PMID: 31684196 [PubMed]
PMID:
PubMed:31684196
DATE FOUND:
11/07/19 01:50PM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31684196?dopt=Abstract
Hope for patients with rare Sjögren’s syndrome
https://medicalxpress.com/news/2019-10-patients-rare-sjgren-syndrome.html
Hope for patients with rare Sjögren’s syndrome
Common and rare forms of vasculitis associated with Sjögren’s syndrome
https://www.ncbi.nlm.nih.gov/pubmed/31644467?dopt=Abstract
TITLE:
Common and rare forms of vasculitis associated with Sjögren’s syndrome.
DESCRIPTION:
Common and rare forms of vasculitis associated with Sjögren’s syndrome.
Curr Opin Rheumatol. 2019 Oct 21;:
Authors: Argyropoulou OD, Tzioufas AG
Abstract
PURPOSE OF REVIEW: Although uncommon, systemic vasculitis is one of the most severe extraglandular manifestations of primary Sjögren’s syndrome (pSS) accounting for the increased morbidity and mortality of the disease. This review aims to describe major previous and recent reports regarding the clinical presentation, prognosis and treatment of systemic vasculitis associated with pSS.
RECENT FINDINGS: Both older and recent pSS cohort studies performed over the past several and recent years, have clearly shown that cryoglobulinaemic vasculitis is the most frequent type of systemic vasculitis accompanying pSS. Antineutrophil cytoplasmic antibody-associated, large and medium vessel vasculitis are described only in sporadic cases. In addition to the overt clinical manifestations of cryoglobulinaemic vasculitis, type II cryoglobulinaemia, glomerulonephritis and purpura have been correlated with increased risk for B-cell non-Hodgkin lymphoma (NHL) in pSS.
SUMMARY: pSS is characterized by autoreactive B and T-cell infiltrates around the epithelial structures of the affected organs, as well as, B-cell hyperreactivity. The latter, is attested by the increased production of autoantibodies, directed against many different organ and nonorgan self-antigens. Vasculitis is a significant and potentially life-threatening complication of the disease depending on the size, localization, histologic type and the pathogenetic mechanisms of the inflammatory process. The potentially irreversible tissue damage, as well as the increased risk for NHL development, prompts the need for early diagnosis and treatment of cryoglobulinaemic vasculitis in pSS.
PMID: 31644467 [PubMed – as supplied by publisher]
PMID:
PubMed:31644467
DATE FOUND:
10/24/19 06:03AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31644467?dopt=Abstract
Primary Sjögren’s syndrome and the eye: update regarding pathogenesis, diagnosis, investigative procedures, and treatment options
https://www.surveyophthalmol.com/article/S0039-6257(19)30283-8/fulltext
https://www.ncbi.nlm.nih.gov/pubmed/31634487?dopt=Abstract
TITLE:
Primary Sjögren’s syndrome and the eye.
DESCRIPTION:
Primary Sjögren’s syndrome and the eye.
Surv Ophthalmol. 2019 Oct 18;:
Authors: Bjordal O, Norheim KB, Rødahl E, Jonsson R, Omdal R
Abstract
Primary Sjögren syndrome is an autoimmune disease that mainly affects exocrine glands such as the salivary and lacrimal glands. In addition, systemic involvement is common. Primary Sjögren syndrome is of particular interest to ophthalmologists as it constitutes an important differential diagnosis in conditions with dry eye disease. Also, ocular tests for more precisely diagnosing and monitoring primary Sjögren syndrome have become increasingly important, and new therapeutics for local and systemic treatment evolve as a result of increased understanding of immunological mechanisms and molecular pathways in the pathogenesis of primary Sjögren syndrome. We provide an update of interest to ophthalmologists regarding pathogenesis, diagnosis, investigative procedures, and treatment options.
PMID: 31634487 [PubMed – as supplied by publisher]
PMID:
PubMed:31634487
DATE FOUND:
10/22/19 06:00AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31634487?dopt=Abstract
A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren’s Syndrome [Completed]
https://www.clinicaltrials.gov/ct2/show/NCT04111341?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren’s Syndrome.
DESCRIPTION:
Condition: Sjögren’s Syndrome
Interventions: Drug: TCM (Gan-Lu-Yin)GLY; Drug: PLACEBO
Sponsor: Chung Shan Medical University
Completed
CLINICALTRIALS.GOV IDENTIFIER:
NCT04111341
FIRST POSTED:
Tue, 01 Oct 2019 12:00:00 EDT
LAST UPDATE POSTED:
10/01/19 06:22PM
STUDY LINK / URL:
https://www.clinicaltrials.gov/ct2/show/NCT04111341?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst
Symptom-based stratification of patients with primary Sjögren’s syndrome: exploring new subtypes
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(19)30042-6/fulltext
Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials
Immune checkpoint molecules: Possible future therapeutic implications in autoimmune diseases such as Sjögren’s syndrome
https://www.sciencedirect.com/science/article/abs/pii/S0896841119305712?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/31564474?dopt=Abstract
TITLE:
Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.
DESCRIPTION:
Related Articles
Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.
J Autoimmun. 2019 11;104:102333
Authors: Huang C, Zhu HX, Yao Y, Bian ZH, Zheng YJ, Li L, Moutsopoulos HM, Gershwin ME, Lian ZX
Abstract
During host immune response, an initial and sufficient activation is required to avoid infection and cancer, yet an excessive activation bears the risk of autoimmune reactivity and disease development. This fastidious balance of the immune system is regulated by co-stimulatory and co-inhibitory molecules, also known as immune checkpoints. Both excessive co-stimulation and insufficient co-inhibition can induce the activation and proliferation of autoreactive cells that may lead to the development of autoimmune diseases. During the last decade, a growing number of new immune checkpoint receptors and ligands have been discovered, providing an attractive approach to investigate their implication in the pathogenesis of autoimmune diseases and their potential role as targets for effective therapeutic interventions. In this review, we focus on the roles and underlying mechanisms of co-stimulatory and co-inhibitory receptors and other molecules that function as immune checkpoints in autoimmune diseases such as systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Sjögren’s syndrome, type I diabetes and inflammatory bowel disease. We also summarize previous and current clinical trials targeting these checkpoint pathways in autoimmune diseases and discuss further therapeutic implications and possible risks and challenges.
PMID: 31564474 [PubMed – indexed for MEDLINE]
PMID:
PubMed:31564474
DATE FOUND:
08/07/20 06:03AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31564474?dopt=Abstract
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren’s Syndrome
https://www.clinicaltrials.gov/ct2/show/NCT04078386
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren’s Syndrome
An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren’s Syndrome
https://www.clinicaltrials.gov/ct2/show/NCT03627065
A Study of INCB050465 in Primary Sjögren’s Syndrome
Brief Summary:
The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren’s syndrome (SS).
Condition or disease Intervention/treatment Phase
Primary Sjögren’s Syndrome
Drug: Parsaclisib
Phase 2
Study Design
Go to sections
Study Type : Interventional
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren’s Syndrome
Actual Study Start Date : September 24, 2018
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : January 31, 2020
Saliva microbiome in primary Sjögren’s syndrome reveals distinct set of disease-associated microbes
https://onlinelibrary.wiley.com/doi/abs/10.1111/odi.13191
https://www.ncbi.nlm.nih.gov/pubmed/31514257?dopt=Abstract
TITLE:
Saliva microbiome in primary Sjögren’s syndrome reveals distinct set of disease-associated microbes.
DESCRIPTION:
Related Articles
Saliva microbiome in primary Sjögren’s syndrome reveals distinct set of disease-associated microbes.
Oral Dis. 2020 Mar;26(2):295-301
Authors: Sharma D, Sandhya P, Vellarikkal SK, Surin AK, Jayarajan R, Verma A, Kumar A, Ravi R, Danda D, Sivasubbu S, Scaria V
Abstract
OBJECTIVE: This study systematically aims to evaluate the salivary microbiome in patients with primary Sjögren’s syndrome (pSS) using 16S rRNA sequencing approach.
METHODS: DNA isolation and 16S rRNA sequencing was performed on saliva of 37 pSS and 35 control (CC) samples on HiSeq 2500 platform. 16S rRNA sequence analysis was performed independently using two popular computational pipelines, QIIME and less operational taxonomic units scripts (LoTuS).
RESULTS: There were no significant changes in the alpha diversity between saliva of patients and controls. However, four genera including Bifidobacterium, Lactobacillus, Dialister and Leptotrichia were found to be differential between the two sets, and common between both QIIME and LoTuS analysis pipelines (Fold change of 2 and p < .05). Bifidobacterium, Dialister and Lactobacillus were found to be enriched, while Leptotrichia was significantly depleted in pSS compared to the controls. Exploration of microbial diversity measures (Chao1, observed species and Shannon index) revealed a significant increase in the diversity in patients with renal tubular acidosis. An opposite trend was noted, with depletion of diversity in patients with steroids. CONCLUSION: Our analysis suggests that while no significant changes in the diversity of the salivary microbiome could be observed in Sjögren's syndrome compared to the controls, a set of four genera were significantly and consistently differential in the saliva of patients with pSS. Additionally, a difference in alpha diversity in patients with renal tubular acidosis and those on steroids was observed. PMID: 31514257 [PubMed - indexed for MEDLINE] PMID: PubMed:31514257 DATE FOUND: 04/15/20 06:13AM LINK / URL: https://www.ncbi.nlm.nih.gov/pubmed/31514257?dopt=Abstract
A Study of RSLV-132 in Subjects With Primary Sjogren’s Syndrome (RSLV-132)
https://www.clinicaltrials.gov/ct2/show/NCT03247686
A Study of RSLV-132 in Subjects With Primary Sjogren’s Syndrome (RSLV-132)
The Challenge of Identifying Sjogren’s Syndrome
The Challenge of Identifying Sjogren’s Syndrome
The main symptoms — dry eyes and mouth, fatigue and limb pain — are common complaints associated with any number of health problems.
Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren’s syndrome
https://f1000research.com/articles/8-1532/v1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719673/
https://www.ncbi.nlm.nih.gov/pubmed/31508200
Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren’s syndrome [version 1; peer review: 2 approved]
Biologics in Sjögren’s syndrome
https://www.sciencedirect.com/science/article/abs/pii/S1043661819310424?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/31415917?dopt=Abstract
TITLE:
Biologics in Sjögren’s syndrome.
DESCRIPTION:
Related Articles
Biologics in Sjögren’s syndrome.
Pharmacol Res. 2019 09;147:104389
Authors: Skarlis C, Marketos N, Mavragani CP
Abstract
The use of biologic disease modifying antirheumatic drugs (bDMARDs) in systemic autoimmune diseases such as rheumatoid arthritis and at a lesser extent in lupus, has been well established. In Sjögren’s syndrome (SS), despite the shared pathogenetic mechanisms with other autoimmune disorders, traditional immunomodulatory drugs have failed to address the main clinical features of the disease and use of biologics has been limited so far. Over the last years, our better understanding in disease pathogenesis has led to an expansion in the number of clinical trials exploring the effect and safety of biological agents with variable results. In the current review, the effect of targeting key molecular mechanisms involved in SS pathogenesis such as antigen presentation, B and T cell activation and germinal center formation is discussed.
PMID: 31415917 [PubMed – indexed for MEDLINE]
PMID:
PubMed:31415917
DATE FOUND:
06/18/20 06:30AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31415917?dopt=Abstract
Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome: CatS inhibition may represent a promising novel treatment strategy in pSS
https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1955-2
https://www.ncbi.nlm.nih.gov/pubmed/31319889?dopt=Abstract
TITLE:
Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome.
DESCRIPTION:
Related Articles
Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome.
Arthritis Res Ther. 2019 07 18;21(1):175
Authors: Hargreaves P, Daoudlarian D, Theron M, Kolb FA, Manchester Young M, Reis B, Tiaden A, Bannert B, Kyburz D, Manigold T
Abstract
OBJECTIVE: Primary Sjögren syndrome (pSS) is characterized by T and B cell infiltration of exocrine glands. The cysteine protease cathepsin S (CatS) is crucially involved in MHCII processing and T cell stimulation, and elevated levels have been found in patients with RA, psoriasis and pSS. However, little is known about the functional characteristics and mechanisms of SS-A- and SS-B-specific T cells in pSS patients. We herein investigated the inhibition of CatS activity in different biocompartments of pSS patients including antigen-specific T cell responses.
METHODS: Ex vivo CatS activity was assessed in tears, plasma and saliva of 15 pSS patients and 13 healthy controls (HC) and in the presence or absence of the specific CatS inhibitor RO5459072. In addition, antigen (SS-A (60kD), SS-B, influenza H3N2, tetanus toxoid and SEB)-specific T cell responses were examined using ex vivo IFN-γ/IL-17 Dual ELISPOT and Bromdesoxyuridin (BrdU) proliferation assays in the presence or absence of RO5459072. Supernatants were analysed for IL-1β, IL-6, IL-10, TNF-α, IL-21, IL-22 and IL-23, using conventional ELISA.
RESULTS: CatS activity was significantly elevated in tear fluid, but not other biocompartments, was inversely associated with exocrinic function in pSS patients and could significantly be suppressed by RO5459072. Moreover, CatS inhibition by RO5459072 led to strong and dose-dependent suppression of SS-A/SS-B-specific T cell effector functions and cytokine secretion by CD14+ monocytes. However, RO5459072 was incapable of suppressing SS-A/SS-B-induced secretion of cytokines in CD14+ monocytes when T cells were absent, confirming a CatS/MHCII-mediated mechanism of suppression.
CONCLUSION: CatS activity in tear fluid seems to be a relevant biomarker for pSS disease activity. Conversely, CatS inhibition diminishes T cell and associated monokine responses towards relevant autoantigens in pSS. Thus, CatS inhibition may represent a promising novel treatment strategy in pSS.
PMID: 31319889 [PubMed – indexed for MEDLINE]
PMID:
PubMed:31319889
DATE FOUND:
08/11/20 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31319889?dopt=Abstract
Potential therapeutic applications of exosomes in different autoimmune diseases including Sjogren’s syndrome
https://www.sciencedirect.com/science/article/abs/pii/S1521661619301548?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/31228581?dopt=Abstract
TITLE:
Potential therapeutic applications of exosomes in different autoimmune diseases.
DESCRIPTION:
Related Articles
Potential therapeutic applications of exosomes in different autoimmune diseases.
Clin Immunol. 2019 08;205:116-124
Authors: Xu H, Jia S, Xu H
Abstract
Autoimmune diseases are caused by self-immune responses to autoantigens, which damage body tissues and severely affect the patient’s quality of life. Therapeutic drugs are associated with adverse side effects and their beneficial effects are limited to specific populations. Evidence indicates that exosomes which are small vesicles secreted by most cell types and body fluids, and may play roles in both immune stimulation and tolerance since they are involved in many processes such as immune signaling, inflammation and angiogenesis. Exosomes have also emerged as promising tools for therapeutic delivery, given their intrinsic features such as stability, biocompatibility and a capacity for stealth. In this review, we summarize existing literature regarding the production, efficacy, action mechanism, and potential therapeutic uses of exosomes in the contexts of autoimmune diseases such as type 1 diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and Sjogren’s syndrome.
PMID: 31228581 [PubMed – indexed for MEDLINE]
PMID:
PubMed:31228581
DATE FOUND:
04/21/20 06:17AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31228581?dopt=Abstract
Sjögren’s syndrome update: Clinical and therapeutic aspects
https://www.sciencedirect.com/science/article/abs/pii/S0248866319304242?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/31027874?dopt=Abstract
TITLE:
[Sjögren’s syndrome update: Clinical and therapeutic aspects].
DESCRIPTION:
Related Articles
Rev Med Interne. 2019 Jul;40(7):433-439
Authors: Nocturne G
Abstract
Sjögren’s syndrome (SS) is a systemic orphan disease. It is characterized by the involvement of epithelial tissues leading to the term of autoimmune epithelitis. New classification criteria have been developed in 2016. New scores have also been developed: a patient-reported outcome called ESSPRI and a score assessing systemic activity of the disease called ESSDAI. These new tools are very helpful to better stratify patients and to customize the management of this very heterogeneous disease. Among the autoimmune diseases, SS is associated with the highest risk of lymphoma. Five to ten percent of the patients will have a B cell lymphoma mostly a low-grade lymphoma developing from mucosa-associated lymphoid tissue (MALT). Major advances have been made in this field: pathogeny is better understood, new predictors are available and progresses have been made in the management of this severe complication. Research in the field of SS is very dynamic as illustrated by the high number of therapeutic trials. There is hope that these innovations, reviewed in the present article, will have potential significant repercussions for the patients in the next few years.
PMID: 31027874 [PubMed – indexed for MEDLINE]
PMID:
PubMed:31027874
DATE FOUND:
05/01/20 06:29AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31027874?dopt=Abstract
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome (TWINSS)
https://www.clinicaltrials.gov/ct2/show/NCT03905525
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome (TWINSS)
AT-RvD1 Restores Function of Salivary Glands, Decreases Harmful T-cells in Mouse Model of Sjögren’s
AT-RvD1 Restores Function of Salivary Glands, Decreases Harmful T-cells in Mouse Model of Sjögren’s
AT-RvD1 Restores Function of Salivary Glands, Decreases Harmful T-cells in Mouse Model of Sjögren’s
Sjögren’s Syndrome: Moisturize Me! – Reddit
https://www.reddit.com/r/Sjogrens/
Sjögren’s Syndrome: Moisturize Me! – Reddit
r/Sjogrens: This is a space for people to discuss our struggles and successes with Sjögren’s. A place to share information and encourage each other.
General Discussion – Sjogren’s Syndrome Support
https://www.sjogrenssyndromesupport.org/c/general/8
Sjogren’s Syndrome Support | General Discussion about topics related to Sjogren’s Syndrome
Sjogren’s World Forums
http://sjogrensworld.org/forums/index.php
http://sjogrensworld.org/forums/index.php?PHPSESSID=43342a14cd1951974f34f50303cffe96&board=1.0
